Targeted Epigenetic Editing Using a dCas9- SunTag Methylation System by Waly, Reema
 












Targeted Epigenetic Editing Using a dCas9-









Supervised by Dr. Aniruddha Chatterjee and Mr. Rob Weeks 
 
 
A thesis submitted in partial fulfilment of the Degree of 
Bachelor of Biomedical Science with Honours. 







DNA methylation is a stable and somatically heritable epigenetic process. It is classically 
understood as a gene silencing mechanism, whereby hypermethylation of gene promoters is 
largely associated with transcriptional silencing. However, emerging research in the past 
decade has found a different association, particularly in the context of cancer and metastasis. 
These studies have demonstrated a seemingly paradoxical correlation between high levels of 
promoter methylation and subsequent transcriptional activation. As such, we are yet to fully 
unravel the complex mechanism underlying this relationship. This warrants further 
investigations to better understand this dynamic molecular mechanism and thus its implications 
in cancer pathobiology and metastasis.   
 
Previously established methods of manipulating DNA methylation have largely involved the 
use of chemical drugs, such as decitabine. These drugs act globally on the epigenome and are 
thus non-specific. Importantly, as they are inhibitors of DNA methylation, they cannot 
definitively demonstrate that an increase in promoter methylation is directly responsible for an 
increase in gene expression. Therefore, by using a CRISPR-based system for targeted 
epigenetic editing, the precise mechanism of paradoxical gene activation by DNA methylation 
can now be investigated.  
 
Our group has recently demonstrated this paradoxical correlation in a study characterising 
epigenetic changes in metastatic melanoma. The Early B-cell Factor 3 (EBF3) gene promoter 
region was found to be substantially hypermethylated in metastatic cell lines compared to 
paired, primary cell lines. This increase in methylation was also found to be associated with a 
subsequent increase in gene expression. These findings suggest that EBF3 in human melanoma 
cell lines is a good candidate gene to investigate this complex relationship. 
 
Here, I aim to establish a methylation editing system and apply it to the EBF3 promoter region. 
This is a three-component CRISPR system incorporating the SUperNova Tag (SunTag), which 
allows for the recruitment of multiple effector proteins. In this project, I use the DNA 
methyltransferase 3A (DNMT3A) effector protein to induce active methylation at a target locus 
within the EBF3 promoter region in melanoma cell lines.  
 
 ii 
Methylation changes have been evaluated using methylation-specific Illumina iSeq 
sequencing. Variable levels of targeted methylation have been observed, of up to 38.0% 
absolute methylation change between edited and unedited samples. This project represents 
important progress in investigating the promoter methylation of EBF3 in more detail, as well 
as laying out an essential platform to further investigate methylation changes and causal 
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Chapter 1: Introduction 
1.1 Epigenetics and DNA Methylation 
Epigenetic changes are classically defined as changes to gene expression that do not involve a 
change to the DNA sequence itself (1). These changes are fundamental to human development 
from the early stages of embryogenesis through to ageing (2, 3). Not surprisingly, the capability 
of epigenetic changes to alter gene expression also implicates them as critical role-players in 
disease. DNA methylation is an extensively studied epigenetic mechanism, and its role in 
disease, particularly in cancer, is currently an active area of research. The initial sections of 
this chapter will focus on the role of DNA methylation in human development, followed by its 
role as a hallmark feature of cancer development and progression. 
 
1.1.1 DNA Methylation in Human Development 
DNA methylation is a somatically heritable and stable silencing mark (2). The process of DNA 
methylation is well understood at the chemical level. It is the addition of a methyl group (-CH3) 
that occurs exclusively at the fifth carbon of cytosine nucleotides within CpG dinucleotides, 
resulting in 5-methylcytosine (5-mC) (2, 3). CpG sites exist in various locations across the 
genome; either within centromeres, transposable elements and other long repetitive sequences, 
or within CpG islands. CpG islands are short CpG-rich regions uniquely associated with the 
promoter regions of genes (3, 4). During human development, CpG islands are usually 
unmethylated to allow genes to be transcribed, whilst other CpG sites across the genome are 
likely methylated to maintain chromosomal stability (5, 6).  
 
Despite the majority of CpG islands remaining unmethylated, CpG island methylation does 
occur in specific contexts to necessitate processes of development.  It plays an important role 
in X-inactivation, genomic imprinting and the maintenance of genomic stability (7, 8). In 
particular, DNA methylation changes are essential to the early development processes of 
embryogenesis and gametogenesis. The DNA methylome initially undergoes reprogramming 
in the zygotic stage prior to implantation, whereby it is globally erased (9). This is necessary 
to ensure the totipotency of the embryo, as the maternal and paternal epigenomes that are 
initially inherited possess their own methylation patterns. 
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The erasure of the paternal and maternal methylomes occurs at different respective stages 
throughout embryonic cell divisions. The paternal genome is the first to be rapidly and actively 
demethylated at the two-cell stage; whereas, the maternal genome is slowly and passively 
demethylated across several cell division stages. The erasure of paternal and maternal 
methylation is also thought to be associated with different enzymes. Paternal genome 
demethylation is mediated by the ten-eleven translocation 3 (TET3) enzyme, whereas maternal 
genome demethylation is mediated by the absence of DNA methyltransferase 1 (DNMT1) 
activity (10). The different enzymes associated with methylation and demethylation are 
explored further in Section 1.1.2. 
 
1.1.2 DNA Methyltransferase Enzymes and the Establishment of 
Methylation 
The methylation reaction is catalysed by DNA methyltransferase enzymes (DNMTs). DNMT 
enzymes are essential for the establishment and maintenance of DNA methylation patterns 
across the mammalian lifespan (2). There are three major mammalian DNMT enzymes: 
DNMT1, DNMT3A and DNMT3B.  
 
The main role of DNMT1 is said to be the maintenance of DNA methylation during the S phase 
of the cell cycle (11). It is constitutively expressed in dividing cells, and it exhibits a high 
affinity for hemimethylated DNA (12). Thus, DNMT1 is able to copy the established 
methylation patterns from the parent cell to the daughter cells. While DNMT1 is considered to 
be the lead player in the maintenance of methylation, the de novo establishment of methylation 
occurs through the DNMT3A and DNMT3B methyltransferase enzymes. All tissues express 
DNMT3A, while only some cells found in the bone marrow, testes and thyroid express 
DNMT3B. Unlike DNMT1, these enzymes do not exhibit a high affinity for hemimethylated 
DNA. Therefore, this allows them to carry out methylation independently of cell division 
whereby they can methylate DNA that was previously unmethylated (13). 
 
1.1.3 Active and Passive Demethylation Pathways 
The erasure of methylation can occur via active or passive demethylation pathways. Active 
demethylation occurs independently of DNA replication, and its initial steps are mediated by 
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the TET family of dioxygenase enzymes: TET1, TET2 and TET3. The TET enzymes convert 
5-methylcytosine (5mC) via oxidation and deamination, the two pathways which have been 
identified to date (14, 15). Active demethylation also involves base excision repair (BER) 
pathways (16). In contrast, passive demethylation occurs during DNA replication and is simply 
the absence of re-methylation. In this scenario, several factors such as compromised DNMT 
enzymes or the absence of essential cofactors would not allow for the successful re-
establishment of methylation (16). While the various pathways involved in demethylation have 
only recently been described in the literature, their importance in maintaining cell physiology 
is widely recognised (17). 
 
1.2 DNA Methylation in Cancer 
Although DNA methylation is an essential player in regular biological processes, it is also well-
established that distinctive and abnormal patterns of methylation have been observed across 
multiple types of cancers (18). This section serves to review the current understandings 
associated with DNA methylation and cancer.  
 
1.2.1 Tumour Development and Progression 
Tumour development and progression is driven by the differential expression of particular 
genes in neoplastic cells. These genes are tumour-suppressor genes and oncogenes which are 
known to be associated with critical processes such as apoptosis and proliferation (19). Cancer 
cells are described to have several key features including the evasion of apoptosis, continued 
growth and proliferation, evasion of the immune system and the ability to spread to surrounding 
tissues (19). These features were coined the ‘hallmarks of cancer’ by Hanahan and Weinberg, 
and they have been consistently recognised across the literature over the past two decades.  
 
Recently, it has become evident that the complex molecular events that lead to cancer are the 
result of both genetic changes and epigenetic events (18). It is thus unsurprising that epigenetic 
aberrations have also been proposed as a defining property of cancer. However, several reviews 
argue that aberrant epigenetic modifications should instead be considered in the same manner 
as genetic modifications; in that they contribute to the acquisition of the hallmark properties of 
cancer rather than being a property themselves (20-22). This understanding is based upon the 
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idea that the behaviour of a cell is dictated by the expression of the genetic information within 
that particular cell. As such, aberrant epigenetic modifications that influence gene expression 
are then capable of influencing a cell’s acquisition of hallmark cancer properties.  
 
1.2.2 DNA Methylation and the Cancer Epigenome 
Recent progress in epigenetic research has identified two key marks of cancer development 
and progression in the epigenome (19, 23). Firstly, the DNA methylation landscape of many 
cancers features a much lower level of DNA methylation in comparison to normal tissue, and 
most cancers are therefore referred to as exhibiting a global loss of methylation. Secondly, 
despite this global loss of methylation, many cancers also feature site-specific promoter 
hypermethylation (18, 24-26). This site-specific hypermethylation is commonly found within 
the promoter regions of tumour-suppressor genes, and it is thought to limit the access of 
transcriptional machinery and therefore encourage transcriptional silencing at the promoter 
region (18). As described previously, these tumour-suppressor genes are commonly involved 
in critical pathways such as DNA repair and apoptosis, and thus it is plausible that 
transcriptional silencing within these genes would lead to a cell’s acquisition of several 
cancerous features (18). 
 
1.2.3 DNA Methylation and Metastasis 
Knowledge of the specific epigenetic changes that drive a primary tumour to transition to 
metastasis is still very limited. One observation is that as cancer progresses to metastasis, the 
key marks of a global loss of methylation and site-specific hypermethylation appear to 
increase (18). This association is unsurprising, considering that as a tumour progresses to 
metastasis it would need to acquire features that allow it to spread further and invade tissues. 
These features could be acquired through aberrant gene expression patterns as a result of an 
increase in site-specific DNA hypermethylation and genome-wide hypomethylation.  
 
It has been suggested that site-specific DNA methylation could have a more direct role in 
promoting a primary tumour to transition to metastasis. The acquisition of specific cellular 
phenotypes, such as resisting cell death, is required for successful metastasis. DNA methylation 
may play a more direct role in facilitating the acquisition of such feautures. For example, 
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specific methylation changes could be occurring within the transcriptional control regions of 
certain genes, allowing for the expression or silencing of those genes which are essential for 
the acquisition of metastatic phenotypes (26, 27). These site-specific DNA methylation 
changes have recently been referred to as ‘epigenetic drivers’ of cancer progression and 
metastasis (27).  
 
While these explanations are probable, further investigations are imperative to 
comprehensively establish the role of epigenetics in cancer. It is thus crucial to identify specific 
DNA methylation changes that occur during tumour development and those that drive 
metastatic progression. 
 
1.3 DNA Methylation and Gene Expression: Current Dogma 
There is a general consensus that the presence of high levels of DNA methylation within the 
promoter region of a gene is associated with transcriptional silencing (2). This is based on 
investigations of this association that have largely found high levels of DNA methylation 
within a gene promoter to be correlated with a decrease in messenger RNA (mRNA) levels, 
and thus a decrease in transcriptional activity associated with that gene (2, 28, 29).  
 
The mechanism by which DNA methylation causes transcription silencing has been 
investigated for decades (30), and it has thus acquired an extensive body of evidence over the 
past few years. Currently, we understand that the presence of methylation leads to the 
recruitment of methyl CpG binding domain (MBD) proteins and transcriptional repressors 
which subsequently induce changes to the local chromatin structure. These changes in the 
chromatin structure limit transcriptional machinery from accessing the DNA, thereby causing 
a repression in transcriptional activity (29). While this is thought to be the role of DNA 
methylation in regulating gene expression, evidence challenging this understanding has 
emerged in the past few years and this will be explored further in the following sections. 
 
1.3.1 Emerging Evidence Challenging the DNA Methylation Dogma 
Despite the substantial body of evidence supporting the correlation between high levels of 
promoter methylation and gene silencing, an increasing number of publications have found 
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promoter hypermethylation to be correlated with gene upregulation across multiple different 
types of cancer (27, 32, 37-45). These paradoxical findings challenge the current dogma of 
DNA methylation, and therefore suggest the need to investigate this phenomenon further. 
Figure 1.1 shows a simple schematic illustrating this paradoxical phenomenon alongside the 














Figure 1.1. DNA Methylation and Gene Expression Profile in the Current Dogma and in 
Paradoxical Findings. (A) Illustrated here is a methylated CpG island in a gene promoter 
corresponding to gene silencing, and likewise an unmethylated CpG island corresponding to gene 
expression. (B) Shown here is the paradoxical finding of methylated CpG islands in gene promoters 
corresponding to gene expression. Image created using BioRender.com. Waly 2020, original work. 
 
 
1.3.2 Potential Mechanisms Facilitating Gene Activation 
With recent evidence suggesting that promoter methylation may be linked to transcriptional 
activation, several mechanisms have been proposed throughout the literature by which this 
could be facilitated.  
 
It is currently understood that transcriptional repressors down-regulate transcription by 
inducing chromatin structural changes and thereby preventing transcriptional machinery from 
accessing the DNA (31). This activity of transcriptional repressors is also known to be 
associated with the presence of highly methylated gene promoters (31). However, several 
publications have hypothesised that it may be possible that the high levels of methylation are 
Paradoxical DNA Methylation and Gene Expression 
A Current DNA Methylation Dogma 
B 
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significant enough that they instead prevent transcriptional repressors from binding, thus 
facilitating gene expression (32-34). 
 
Another potential mechanism that has been proposed in the literature is the expression of a 
gene from an alternative promoter. Promoters are generally defined as one or more region 
within a particular gene at which RNA polymerase can bind and initiate transcription (35). It 
is not uncommon for mammalian genes to have multiple promoter regions whereby 
transcription can be initiated. Additionally, it is also known that the same protein can be 
generated despite transcription from alternative promoters. It therefore is not implausible that 
transcription from an alternative promoter is possible in the event of hypermethylation of the 
known promoter of a gene (36). 
 
1.3.3 Melanoma and Other Cancers  
Some of the initial findings in the literature were related to the hTERT gene which has long 
thought to play a large role in telomerase activation in multiple types of cancer (37). Promoter 
hypermethylation of hTERT has been correlated with an increase in transcriptional activity 
across several studies including colorectal cancer, HPV-induced carcinogenesis and brain 
tumours (37-41). Contrastingly, hypomethylation and a corresponding lack of hTERT 
expression was also found. Other reports of this correlation have also been found within the 
context of cell lines, where for example Parashar et al. found transcriptional activation of 
the TIMP2 gene despite promoter hypermethylation in cervical cancer cell lines (42). Several 
of these publications are summarised in Table 1.1. 
 
In more recent years, comparing primary and metastatic melanoma has generated several key 
findings that support the idea that promoter hypermethylation and corresponding gene 
expression may play a key role in the transition to metastasis. In a 2016 publication, Chatterjee 
et al. analysed The Cancer Genome Atlas (TCGA) datasets, and identified five genes 
(MGMT, HOXD12, GATA4, ESR1 and TWIST1) that display a correlation between increased 
promoter methylation and increased gene expression (43). This analysis compared both 
primary and metastatic melanoma patient cohorts with statistically significant findings, further 




Table 1.1 Examples of Publications Showing a Correlation Between High Promoter 
Methylation and Gene Expression. Adapted from Smith et al. (2020) (36). 
Gene Cancer Type Description Reference 
hTERT Pan-Cancer Hypermethylation of hTERT was associated 
with increased expression in both tumour 
cell lines and tissue samples compared to 
normal tissue 
(37-41) 
TIMP2 Cervical Promoter hypermethylation of TIMP2 
correlated with increased gene expression 
(42) 
EBF3 Melanoma Increased promoter methylation associated 
with increased EBF3 expression in 






Hypermethylation associated with 
increased EBF3 expression 
(44) 
MGMT Melanoma Increased promoter methylation associated 
with increased mRNA levels 
(43) 
HOXD12 Melanoma Increased promoter methylation associated 
with increased mRNA levels 
(43) 
GATA4 Melanoma Increased promoter methylation associated 
with increased mRNA levels 
(43) 
PAX2 Endometrial Increased methylation associated with 
increased PAX2 mRNA and protein  
(32) 
Multiple Pan-Cancer 29.5% of genes displayed promoter 
methylation positively correlated with gene 
expression across 33 cancer types  
(45) 
 
1.4 Establishing Causality Between DNA Methylation and Gene 
Expression 
Notwithstanding their significant findings, these studies remain limited in that they do not 
provide evidence of direct causality between promoter DNA methylation and subsequent gene 
expression. Investigating this causality is a necessary step forward to test the feasibility of a 
new principle. Thus, there is substantial justification for future research to address this 
relationship and particularly in the context of melanoma, using the EBF3 gene as a potential 
model.  
 
The main limitation of the previously discussed studies is their global approach to the 
manipulation of DNA methylation. For example, in the use decitabine, a drug which inhibits 
DNA methylation. Decitabine acts globally on the genome and therefore cannot target specific 
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promoter loci. Importantly, as it is an inhibitor of DNA methylation, it cannot definitively 
demonstrate that an increase in promoter methylation is directly responsible for an increase in 
gene expression. To overcome this limitation, a more robust investigation of this relationship 
is required. In particular, this should entail the manipulation of DNA methylation at a specific 
locus with minimal off-target effects. This will therefore only be possible with the utilisation 
of new and highly specific epigenome-targeting tools. The next section will briefly review the 
current technology available for DNA methylation editing, culminating in the review of a 
system capable of greater specificity and the system utilised in this project.  
 
1.4.1 The EBF3 Gene: A Potential Epigenetic Driver of Metastasis in 
Melanoma 
Chatterjee et al. (2017) conducted a study which compared primary and metastatic melanoma 
cell lines and found promoter hypermethylation in the EBF3 gene to correlate with an increase 
in mRNA levels (27). This study also treated the cell lines with decitabine (5-aza-2′-
deoxycytidine), a DNA methyltransferase inhibitor (DNMTi), to remove methylation and 
likewise found a respective decrease in EBF3 mRNA levels. The specific region which was 
found to be hypermethylated is a 58 bp region consisting of nine CpG sites within the EBF3 
promoter region. These EBF3 methylation patterns have also subsequently been observed in 
colon tumours and prostate tumours, further validating the role of EBF3 as a potential 
epigenetic driver of metastasis in melanoma (44). These findings suggest that EBF3 in human 
melanoma cell lines is a good candidate gene to investigate this paradoxical relationship, and 
is therefore the focus of the work described in this thesis. The justification and the specific 
approach to this investigation will be explored further in the sections below. 
 
1.5 Editing the Epigenome: The Current Technologies of Targeted 
DNA Methylation Editing 
In order to understand the implications of epigenetic changes on the behaviour of an individual 
cell and eventually on a larger scale, the specific manipulation of the epigenome must be 
possible. There are various existing technologies which have been utilised to manipulate DNA 
methylation, such as DNA bindings proteins, however the recent discovery of (Clustered, 
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Regularly Interspaced Short Palindromic Repeats) CRISPR-based methods have allowed for 
more specific and targeted methylation-editing to become a reality (46).  
 
1.5.1 DNA-Binding Proteins 
The era of targeted genome and epigenome editing began with the discovery of DNA-binding 
proteins. The first to be utilised were zinc-finger (ZNF) proteins and later, transcription 
activator-like effector proteins (TALEs). ZNFs are able to recognise and bind to a specific 
DNA sequence, with each individual zinc finger able to recognise a DNA sequence of three 
base pairs (47). TALEs come from Xanthomonas bacteria and rather than three base pairs, they 
are able to specifically recognise and bind to one single base pair (48-50). Both ZNFs and 
TALEs can be chimerically fused to a DNA cleavage domain to function as a ‘programmable’ 
nuclease with a higher specificity for binding DNA at a target locus. 
 
ZNF and TALE techniques however are not without their limitations. Each target site of 
interest requires a newly designed and engineered set of proteins, making for an onerous 
technique that has not widely been utilised by the research community. However, the 
applicability of CRISPR-based technology in the context of  epigenomic editing has allowed 
for potentially enhanced levels of efficacy with a powerful system that is both simpler and 
more easily achievable (51).  
 
1.5.2 The CRISPR System 
Originally discovered as a bacterial adaptive immune response against invading bacteriophages 
and other exogenous elements, the CRISPR and CRISPR-associated (Cas) enzyme system has 
become a fundamental tool in molecular biology research (52). The system used in this project 
is the type II CRISPR system from Streptococcus pyogenes.  
 
1.5.2.1 CRISPR-dCas9 for Methylation Editing 
There are specific differences between genome-editing based CRISPR systems and when the 
type II CRISPR system is applied for editing DNA methylation in the epigenome. There are 
three essential components for editing DNA methylation: a DNA binding protein, a unique 
guide RNA (gRNA) and an effector protein.  
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Firstly, cleavage of the target DNA is not required when altering DNA methylation. Therefore, 
the catalytic activity of the Cas9 nuclease is removed and the resultant DNA binding protein is 
termed dCas9 or catalytically dead Cas9 (53, 54). To remove its catalytic activity, the dCas9 
has mutations in the HNH and RuvC-like domains. These mutations result in single-amino acid 
substitutions that convert aspartic acid to alanine and histidine to alanine, respectively (53). 
 
Secondly, CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA), can be 
chimerically fused to form a single guide-RNA (gRNA or sgRNA) (54). The gRNA molecule 
can then be easily designed to target any locus of interest by modifying the 20 base-pair spacer 
components. Additionally, there are 5´-NGG-3´ protospacer-adjacent motif (PAM) 
requirements for this particular system, whereby the target sequence should immediately 
proceed the PAM site (55). 
 
Finally, this CRISPR-dCas9 system can be fused to the DNMT3A enzyme for targeted 
methylation editing, and that is the basis for the system utilised in this thesis. Similarly, 
CRISPR-dCas9 can also be fused with TET proteins to stimulate demethylation at the target 
locus, however these will not be extensively described here (51). Overall, various DNMT3A-
dCas9 tools have been optimised and utilised for targeted methylation editing. Table 1.2 lists 
the recent publications which have utilised these tools and their distinctive features. 
 
Table 1.2. Recent Publications Using CRISPR-dCas9-DNMT3A Methylation Editing 
Tools. Adapted from Urbano et al. (2019) (46). 
dCas9 Tool Used Features 
dCas9-DNMT3A (56) Full DNMT3A protein 
dCas9-DNMT3ACD (57) Catalytic domain of DNMT3A (DNMT3ACD) 
dCas9-DNMT3ACD-DNMT3L 
(58-59) 




A chimeric MTase of dCas9 seperately fused to either 
DNMT3A, DNMT3L or Krupple-associated box 
(KRAB) proteins 
dCas9-SunTag-DNMT3A (61) SUperNova Tag (SunTag), a repeating peptide array 
able to recruit multiple copies of DNMT3A 
dCas9-MQ1 (62) dCas9-MQ1 fusion protein (M.SssI), 
derived from Mollicutes spiroplasma 
dCas9-SunTag-DNMT3ACD (63) SunTag and DNMT3ACD 
dCas9-Split M.SssI (64) Split catalytic domain and M.SssI 
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Despite the utility of an easily programmable gRNA sequence, both CRISPR-dCas9-DNMT3A 
and CRISPR-dCas9-TET systems for inducing methylation and demethylation respectively, 
have shown substantial off-target activity (65). This has prompted several research studies to 
incorporate additional components to decrease the levels of off-target activity, and thus 
increase the specificity of the system. The system used in this project, the SUperNova Tagging 
(SunTag) system, is able to reduce non-specific activity and is described in the following 
section. 
 
1.5.3 The CRISPR-dCas9-SunTag System 
The SunTag, developed by Tanenbaum et al. (2014), is a repeating peptide array capable of 
recruiting multiple copies of an antibody-fusion proteins (66). It was originally developed for 
the amplification of fluorescence signals during imaging; however, it has also been tested in 
the context of CRISPR-dCas9, where the SunTag scaffold is fused with the dCas9 protein. The 
literature has favourably shown the CRISPR-dCas9-SunTag system to have significantly 
improved both the efficacy and the specificity of targeted DNA methylation editing. It has 
successfully been applied for methylation and demethylation across several studies in the past 
few years, with minimal off-target effects on the global methylome (61, 63, 67-70).  
 
The specificity and efficacy of the SunTag system is supported by several studies which have 
compared CRISPR-dCas9-SunTag-based systems to CRISPR-dCas9 systems which do not 
include the SunTag component (61, 63). For example, by using reduced representation bisulfite 
sequencing (RRBS) and RNA-seq analysis, Huang et al. compared the off-target effects of a 
dCas9 system fused with DNMT3A with and without the SunTag component (61). This study 
found that the dCas9-SunTag system did not have genome-wide effects on methylation. They 
also concluded that the use of dCas9 in conjunction with only the catalytic domain of the 
DNMT3A enzyme (DNMT3ACD) resulted in significant off-target effects on methylation. 
Likewise, in another study, Pflueger et al. used chromatin immunoprecipitation sequencing 
(ChIP-seq) and Illumina EPIC target solution capture bisulfite sequencing (TSC-bs-seq) and 
found the dCas9-SunTag-DNMT3A system to have very low off-target effects compared to a 
dCas9-DNMT3A system without the SunTag component (63).  
 
Overall, the addition of the SunTag has consistently shown increased specificity by targeting 
the DNMT3A enzymes to a specific locus more efficiently. There is substantial evidence to 
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support the use of the CRISPR-dCas9-SunTag system as an efficient tool for DNA methylation 
editing in preference over other systems, and will therefore be utilised in this project for the 
targeted methylation editing of the EBF3 promoter region (36, 46). The components of the 












Figure 1.2. Schematic of the Three Components of the CRISPR-dCas9-SunTag system. On the left 
is the CRISPR-dCas9 protein shown in blue with the fused SunTag component, in the middle is the 
single-guide (sgRNA) construct with a red section denoting the unique gRNA sequence and on the right 
is the DNMT3A enzyme in green. Image created using BioRender.com. Waly 2020, original work. 
 
1.6 Aims and Significance of this Project 
Despite the emerging body of evidence challenging the current understanding of the 
relationship between DNA methylation and gene expression, a causal relationship is yet to 
be established. Site-specific DNA methylation may play a direct role in cancer development 
and particularly in tumour progression to metastasis, and it is therefore crucial to the 
understanding of epigenetics in cancer.  Recent research provides preliminary evidence that 
suggests there may be a paradoxical relationship at play between high levels of promoter DNA 
methylation and increased gene expression. This increased gene expression could facilitate 
epigenetic drivers of metastasis, and this has been suggested in recent publications. However, 
the existing studies have only demonstrated such effects via the use of non-specific methods. 
With the advent of new technology, it is now essential to move away from global approaches 
such as DNMTis and towards more specific methods such as the dCas9-SunTag system. 
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The EBF3 gene, implicated as a potential epigenetic driver of melanoma metastasis, can serve 
as potential candidate gene to investigate this relationship, and is the focus of the work 
described in this thesis.  
 
1.6.1 Aims 
This project aims to establish a dCas9-SunTag-DNMT3A system to induce methylation within 
the EBF3 promoter region, and particularly with regard to the nine CpG sites discovered by 
Chatterjee et al. (2017) (27). The major aims are as follows: 
 
1. Purify and confirm the essential plasmids required for transfection of the dCas9-
SunTag-DNMT3A system. 
 
2. Successfully transfect two human melanoma cell lines with the dCas9-SunTag-
DNMT3A system to induce site-specific gain of DNA methylation at the EBF3 target 
region. 
 
3. Use fluorescence-activated cell sorting (FACS) to generate a pure population of cells 
which have been successfully transfected with all components of the dCas9-SunTag-
DNMT3A system. 
 
4. Perform methylation-specific Illumina iSeq sequencing analysis of the 285 bp region 
of the EBF3 promoter to evaluate DNA methylation changes in edited cells.  
 
 
The completion of the above aims will lay out an essential platform to further investigate 
methylation and causal mechanisms of gene expression changes. Following the optimisation 
of the CRISPR-dCas9-SunTag system to edit methylation in the context of EBF3 and 
melanoma cell lines, extensive gene expression studies can be performed to investigate whether 
changes in DNA methylation will cause changes in gene expression. By beginning to address 
the gaps in our understanding of this paradoxical relationship, these objectives may also 
contribute to establishing the role of EBF3 and a potential epigenetic driver of melanoma 
metastasis.  
 15 
Chapter 2: Isolation and Confirmation of  
CRISPR System Plasmids 
2.1 Introduction 
This chapter describes the components of the CRISPR system used throughout this project, and 
the isolation and confirmation of all components prior to transfection in human melanoma cell 
lines. 
 
2.1.1 Components of the CRISPR-dCas9-SunTag Methylation System 
This CRISPR-dCas9-SunTag system offers an added layer of efficiency over existing CRISPR-
dCas9 systems for methylation editing (61, 63). This system requires three major components 
to function, illustrated in Figure 2.1. Each construct is also tagged with a unique fluorescence 
protein which enables accurate identification of the cells which have taken up all three 
components, an important requirement of transfection experiments (See Chapter 3, Section 
3.1.2.1).  
 
The first component of the system is the dCas9-SunTag construct. This is composed of the S. 
pyogenes CRISPR protein coding sequence and a dCas9 nuclease domain fused to the SunTag. 
Deactivation of the Cas9 nuclease removes its catalytic activity, resulting in a construct without 
the capacity to directly cleave the DNA sequence (71). The SunTag component comprises 
multiple copies of the GCN4 peptide, which is capable of binding to the scFv antibody in the 
DNMT3A construct (66). The dCas9-SunTag construct is also tagged with a monomeric blue 
florescent protein (mTagBFP). As previously described in in Chapter 1 (Section 1.5.3), the 
addition of the SunTag has consistently shown increased specificity by targeting the DNMT3A 
enzymes to a specific locus more efficiently, and thereby reducing off-target effects (61, 63). 
 
The second component of the system is the scFv-DNMT3A construct which is comprised of 
the human DNMT3A methylation enzyme fused to the scFv antibody domain. The DNMT3A 
enzyme is necessary to actively methylate the target 5mC residues, while the scFv antibody 
serves to allow binding of the DNMT3A construct to the dCas9-SunTag protein (61, 66). The 
DNMT3A construct is also tagged with a superfolder green fluorescent protein (sfGFP). Both 
the DNMT3A construct and the dCas9-SunTag construct are expressed from the simian virus 
(SV40) gene promoter. The third component of the system is the gRNA which comprises of a 
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sgRNA scaffold sequence and a unique gRNA sequence, expressed from an upstream U6 
promoter. A far-red fluorescent protein (TagRFP657) is also tagged to each gRNA molecule.  
 
The three major components of the system work together to achieve methylation editing at a 
specific genomic locus. The gRNA guides the dCas9-SunTag machinery to the specific locus, 
while the GCN4 peptides of the SunTag are capable of binding the scFv antibody domain of 
scFv-DNMT3A construct, therefore recruiting multiple DNMT3A enzymes to the genomic site 


















Figure 2.1. Schematic Overview of the dCas9-SunTag-DNMT3A Methylation-Editing System. 
(A) Illustrated here are the three components required for targeted methylation-editing a specific locus 
in the genome: the CRISPR-dCas9 protein fused to the SunTag.; a unique gRNA sequence (red) fused 
to the sgRNA plasmid; and the DNMT3A protein fused to the scFv antibody domain (pink). (B) Depicts 
the action of all three components of the system at a target site in the genome. First, the sgRNA binds 
to the target site. Then, the CRISPR-dCas9-SunTag protein can recognise and bind to the sgRNA at the 
target site. Next, the scFv domain of the scFv-DNMT3A proteins form antibody-peptide complexes 
with the GCN4 peptide of the SunTag. This action allows multiple copies of the DNMT3A protein to 
access the target site and initiate active methylation of surrounding CpG sites. The red lollipops indicate 
methylated CpG sites, and the green lollipops indicate unmethylated CpG sites. Image created using 





2.1.2 Construction of the System 
The plasmids used in this project have been previously constructed prior to the commencement 
of this work (Chatterjee Group, University of Otago). PCR amplification, TOPO-TA cloning 
and ligation were performed to successfully construct all components of the CRISPR-dCas9-
SunTag system for demethylation and methylation editing. Subsequently, the demethylation 
constructs were transfected into human melanoma cell lines and successful demethylation was 
observed (72). The sections below detail the specific plasmids used in this project for 
methylation editing. A summary of the different plasmid features can be found in Table 2.1. 
 
2.1.2.1 dCas9-10xGCN4 and dCas9-5xGCN4 Plasmids 
Two versions of the dCas9-SunTag were used in this project, differing in the number of GCN4 
motifs, as they have demonstrated different efficacies (70). The pHRdSV40-dCas9-
10xGCN4_v4-P2A-BFP plasmid (10x-dCas9) was developed by Tanenbaum et al. (2014) and 
used by the Chatterjee Group for triple-transfections using the TET1CD demethylation system 
(66). It was sourced from Addgene (catalogue #60903) and propagated within DH5α competent 
E. coli cells.  
 
Further work has been published investigating the effectiveness of GCN4 motifs for 
demethylation, and Morita et al. (2016) developed the pCAG-dCas9-5xPlat2AfID (5x-dCas9) 
plasmid which demonstrated more effective demethylation (70). This plasmid was also 
previously acquired by the Chatterjee Group and modified to include the BFP tag. Both 10x-
dCas9 and 5x-dCas9 have been sequenced and confirmed prior to the commencement of this 
project. 
 
2.1.2.2 DNMT3A and DNMT3A-IM Plasmids 
The DNMT3A plasmid contains the active human DNMT3A protein. Additionally, a plasmid 
with the inactive variant of the DNMT3A protein (DNMT3A-IM) is used as a negative control 
on this project. The plasmids were constructed previously (Chatterjee Lab Group, University 
of Otago) by amplifying the DNMT3A and DNMT3A-IM inserts from Fuw-dCas9-DNMT3A 
and Fuw-dCas9-DNMT3A_IM, sourced from Addgene (catalogue #84476 and #84478 
respectively) (72). Each respective PCR product was then cloned and ligated into the final 
vector pHRdSV40-scFv-GCN4-sfGFP-VP64-GB1-NLS (pHRdSV40), sourced from Addgene 
(catalogue #60904). These plasmids were present in DH5α competent cells, and the DNA was 
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required to be isolated to an optimal concentration and purity for the targeted-methylation 
experiments in this project.  
 
2.1.2.3 gRNA_474+ and gRNA_472- Plasmids 
A total of six unique gRNA plasmids were previously designed prior to the commencement of 
this project (Chatterjee Group, University of Otago). Initial experimental data using the 
TET1CD demethylation system found that two gRNAs constructs, gRNA_474+ and 
gRNA_474-, showed the most substantial levels of demethylation in three melanoma cell lines. 
These gRNAs are located upstream of the target region. Based on this data, these constructs 
were selected for use in this project.  
 
Table 2.1. Summary of Plasmid Features 
 





10 GCN4 motifs 14,511 BFP 
dCas9-SunTag-5x 5 GCN4 motifs 14,404 BFP 
gRNA_474+ 




Upstream of target region  
(antisense strand) 
7,396 RFP 
DNMT3A Active full-length protein 12,432 GFP 
DNMT3A-IM Inactivated protein (smaller in size) 10,600 GFP 
 
2.1.3 Aim 
The major aim of the work described in this chapter is to successfully isolate the DNMT3A 
and DNMT3A-IM plasmids from DH5α competent cells, and to confirm their usability for 
transfection experiments via diagnostic restriction endonuclease digest and Sanger sequencing. 
The dCas9-SunTag and gRNA plasmids were sequenced and confirmed prior to this work, and 
their concentration and purity measurements were reconfirmed. For the purposes of this 
project, these plasmids were required at an optimal concentration, quantity and purity for the 
transfection of cell lines for targeted methylation editing (Chapter 3).  
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2.2 Materials and Methods 
2.2.1 DNA Preparation 
Plasmid DNA was prepared by isolating DNA from previously frozen glycerol stocks of DH5α 
E. coli competent cells. The glycerol stocks were streaked onto LB agar plates with 100 μg/mL 
ampicillin and incubated overnight at 37°C. The following day, single colonies were picked 
and inoculated into 5 mL LB broth with 100 μg/mL ampicillin and cultured for 6 hours at 37°C, 
shaken at 200 rpm. This culture was then inoculated into a larger volume of 400 mL with 100 
μg/mL ampicillin and cultured overnight at 37°C, shaken at 200 rpm. The 400 mL overnight 
culture was then purified using the GenCatch TM Plasmid DNA Maxi Prep Kit (Epoch Life 
Science), as per the manufacturer’s protocol. Each purified construct was stored at -30°C, ready 
for transfection experiments. 
 
2.2.1.1 Concentration and Purity measurements 
The concentration and purity of each plasmid DNA was measured using the NanoPhotometer® 
N120 before storage to ensure optimal quality for the transfection experiments of this project 
(Described in Chapter 3). This was also necessary to correctly calculate the appropriate amount 
of DNA to transfect. If the purified plasmid DNA was determined to be of low quality, the 
preparation was repeated until optimal results were achieved.  
 
2.2.2 Diagnostic Restriction Digests 
As an initial verification of the DNMT3A and DNMT3A-IM plasmids, a diagnostic restriction 
endonuclease  digest was performed and visualised via gel electrophoresis. Restriction 
enzymes were selected by first performing an in silico digest using the ApE software (version 
2.0.61), and selecting enzymes that would yield diagnostic fragments for easy visualisation by 
gel electrophoresis. Restriction digest reactions were performed at 37°C for 1 hour. A 1% 
agarose gel was used, and gel electrophoresis was run at 100V for 30 minutes. The DNA was 
then detected by visualisation through UV gel documentation (gel doc). 
 
Alongside DNMT3A and DNMT3A-IM, the originally sourced plasmid pHRdSV40, which 
comprises the DNMT3A and DNMT3A-IM plasmid backbones, was digested for comparison. 
The restriction enzyme XhoI was selected as it is expected to cut both within the insert and 
within the plasmid backbone. Reagents for the XhoI digest of DNMT3A, DNMTA-IM and 
pHRdSV40 are listed in Table 2.2.  
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Table 2.2.  Reagents Used for Restriction Digest Confirmation of DNMT3A, DNMT3A-
IM and pHRdSV40 Plasmids with XhoI Single Digest  
 
 
2.2.3 Sanger Sequencing 
Purified DNMT3A and DNMT3A-IM plasmid DNA were sequenced for confirmation by 
Genetic Analysis Services, Department of Anatomy, University of Otago, using multiple 
primers to cover the entire insert region (listed in Appendix A). Each sequencing mix was 
prepared as per guidelines provided by Genetic Analysis Services. Sequencing results were 
processed and analysed using Geneious Prime ® software (version 2020.1.2) and aligned to 
the original DNMT3A and DNMT3A-IM plasmid sequence for validation. 
 
  
Reagent XhoI Single Digest 
Anza 10x Buffer 2 μL 
Anza XhoI Enzyme 1 μL 
Milli-Q H2O 16 μL 
Plasmid DNA 1 μg  
Total 20 μL 
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2.3  Results 
2.3.1 Concentration and Purity measurements  
An optimal concentration of each plasmid was successfully confirmed, and the appropriate 
purity measurements were observed. The measurements are listed in Table 2.3 below. 
 
Table 2.3. NanoPhotometer Concentration and Purity Readings for each Plasmid 
 
 
2.3.2 Diagnostic Restriction Digests 
Restriction digests of the DNMT3A and DNMT3A-IM plasmids were performed as detailed 
in Table 2.2, and the expected digest products were confirmed by gel electrophoresis (Figure 
2.2). The expected band sizes for DNMT3A were 8,507 bp, 2,634 bp and 1,300 bp (Figure 
2.2.A), and the expected band sizes for DNMT3A-IM were 8,507, 1,300 and 793bp (Figure 
2.2.B).  
 
Additionally, the original plasmid pHRdSV4, without the DNMT3A or DNMT3A-IM insert 
was also digested alongside for comparison. pHRdSV40 also contains two XhoI restriction 
sites, therefore, it was also expected to be digested and visualised as two fragments of 8,774 






10x dCas9-SunTag 1296 1.9 2.3 
5x dCas9-SunTag 1354 1.8 2.3 
DNMT3A 1642 1.9 2.3 
DNMT3A-IM 1281 2.0 2.4 
gRNA 474+ 177 1.7 2.0 


































Figure 2.2. Agarose Gel Image of Confirmed DNMT3A and DNMT3A-IM Insert Constructs XhoI 
Restriction Digests. (A) DNMT3A plasmid, (B) DNMT3A-IM plasmid and (C) pHRdSV40 plasmid. 
Product from each restriction digest is visualised for the DNMT3A and DNMT3A-IM constructs prior 
to use for transfection. Plasmid maps are shown for each construct, with the XhoI restriction enzyme 
cut site labelled. The SV40 promoter and GFP tag is also labelled. The expected size of each band is 
also noted for reference (blue arrow). The first lane of each contains 0.5 μg of 1 kb Plus DNA Ladder 
for sizing reference. The second lane of each contains undigested DNA, and the third lane contains 
digested DNA. The bands for each undigested construct and restriction digests are present as expected, 





































































2.3.3 Sanger Sequencing  
As described in Section 2.2.3, Sanger sequencing was used for final confirmation of the 
DNMT3A and DNMT3A-IM constructs. The results confirmed the sequence of each plasmid 
using the primer sequences found in Appendix A. Most of the reads aligned to the original 
sequence with high Loss of Resolution (LOR). The sequence of both the DNMT3A and 
DNMT3A-IM inserts aligned to the original sequence with 90% coverage and 96% identity. 
 
Overall, this chapter summarises the purification and confirmation of all the plasmids 




2.4 Statement of Contribution 
Rakesh Banerjee (PhD Candidate, Chatterjee Laboratory, University of Otago) supervised in 
performing the plasmid purification experiments. I have performed all the further experiments, 
generated the presented data and the figures.  Dr. Aniruddha Chatterjee and Rob Weeks 








Chapter 3: Transfection of the DNMT3A Methylation 
System into Human Melanoma Cell Lines 
3.1 Introduction 
Using the three-component dCas9-SunTag system described in Chapter 2, the experiments in 
this chapter detail the principles, techniques and protocols for the transfection of this system 
into human melanoma cell lines. The use of this system for methylation editing with DNMT3A 
in melanoma cell lines is yet to be investigated. The demethylation system differs in that it uses 
the TET1CD effector protein for active demethylation rather than DNMT3A. 
 
3.1.1 Principles of Transfection 
Transfection is a powerful technique that introduces foreign nucleic acids into eukaryotic cells. 
It enables the production of genetically modified cells to study specific genes of interest and 
their effects (73). There are multiple methods of transfection, but they can be divided broadly 
into two types: stable and transient transfections. With stable transfections, the foreign genetic 
material that is introduced into the cell is enduringly present and can be inherited by daughter 
cells (73). It may be integrated into the genome, or remain episomal while still replicating 
independently. This can create a ‘stable’ cell line which continues to express the transfected 
material through successive generations. Contrastingly, transient transfections differ in that the 
introduced genetic material is not integrated into the genome, and as the plasmid DNA is non-
replicating, it will be degraded by nucleases and eventually lost. 
 
3.1.2 Principles of Flow Cytometry  
3.1.2.1 Flow Cytometry and FACS 
Flow cytometers are commonly used laboratory instruments to detect the fluorescent 
characteristics of individual cells (74). The principle of flow cytometry involves cells passing 
single file in a liquid stream through a laser beam which excites the cells. This excitement 
causes light to scatter at two specific angles which enables the assessment of size and structure, 
referred to as forward-scatter (FSC) and side-scatter (SSC), respectively. Modern flow 
cytometers contain multiple lasers and filters that permit excitation and detection of specific 
fluorophores, allowing for the identification and separation of a particular population of cells 
based on multiple fluorescent signals (75). 
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Fluorescent activated cell sorters (FACS) are a specialised type of flow cytometers that can 
identify and separate cells based upon their fluorescence signals, a process known as cell 
sorting (75). Fluorescent-labelling is the most widely used technique to sort cells of interest, 
and it is most commonly achieved by staining with a fluorescent antibody or by expressing a 
fluorophore-tagged protein (76). With regard to this project, the three plasmids transfected into 
melanoma cell lines are tagged with different fluorophores: mTagBFP, sfGFP or TagRFP657. 
Principally, the cells which have taken up each respective plasmid will express the active 
protein of that plasmid; and the fluorophore, expressed via the same promoter, will also be 
synthesised. Each fluorophore is detected by a laser with a different wavelength (75). 
Therefore, cells expressing one or more fluorophore can be separated into distinct populations, 
and cells that are positive for all three plasmids of the DNMT3A methylation system can be 
sorted into a pure population. 
 
3.1.2.2 Live-Dead Cell Exclusion 
When sorting cells using FACS, it is necessary to exclude the dead or apoptosing cells, as they 
may exhibit autofluorescence, which can lead to false positives and inaccurate cell-sorting. 
Although the physical characteristic of the cells to be sorted, i.e. their forward scatter (FSC) 
and side-scatter (SSC), can be used to exclude debris and some dead cells, it is not enough to 
exclude them all. Thus, it is necessary to use dyes to stain cells in order to efficiently distinguish 
the dead or apoptosing cells from the live, healthy cells. For the experiments in this project, the 
LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (Invitrogen) was used. This particular stain 
works by reacting with cellular proteins and producing a fluorescent signal that can be detected 
by flow cytometry. The stain cannot penetrate the cell membrane, therefore only those with a 
compromised cell membrane will be able to take up the stain, allowing for efficient exclusion 
of the dead and apoptosing cells. 
 
3.1.3 Aim 
The aim of the work described in this Chapter is to successfully transfect the CRISPR-dCas9-
SunTag-DNMT3A system into two melanoma cell lines and collect triple-transfected cells by 
FACS. 
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3.2 Materials and Methods 
3.2.1 Cell Line Selection 
As previously described (Chapter 1, Section 1.4. 1), a 58 bp region within the EBF3 gene 
promoter region was found to be substantially hypermethylated in metastatic cell lines 
compared to paired, primary cell lines. This increase in methylation was also found to be 
associated with a subsequent increase in gene expression. As such, to investigate DNA 
methylation and gene expression using the DNMT3A-SunTag methylation system, appropriate 
cell lines that have low levels of EBF3 expression should be selected. Additionally, in order to 
test the efficacy of the DNMT3A-SunTag system to increase methylation in these cell lines, 
the cell lines will need to have lower levels of methylation in the target region. 
 
Previously published and unpublished Reduced Representation Bisulfite Sequencing (RRBS) 
and quantitative reverse transcription polymerase chain reaction (qRT-PCR) data was used to 
select the appropriate cell lines for this project (Chatterjee Lab Group, University of Otago) 
(77). A total of three candidate cell lines were selected. Based on unpublished qRT-PCR data, 
all three selected cell lines have low levels of EBF3 expression. The DNA methylation levels 
within the 58 bp target region for each respective cell line are summarised in Table 3.1 below.  
 
Table 3.1.  Average Baseline DNA Methylation Levels for Candidate Cell Lines within 
the EBF3 Target Region 
 
Cell Line Average DNA Methylation Level  
WM115 61.8 % 
JL-PRE 13.43 % 
EH-POST 2.23 % 
 
The WM115 cell line was obtained from America Type Culture Collection (ATCC) 
(Manassas, VA) in October 2013 with ATCC certificates of analysis and authentication. Two 
further patient melanoma cell lines, JL-PRE and EH-POST were generously obtained from 
the Roche “BRIM II” phase II study (78). 
 
Additionally, prior to the commencement of this project, all cell lines have been validated by 
short tandem repeat (STR) profiling and tested for mycoplasma contamination.  
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3.2.1.1 Cell Culture Conditions 
The WM115 cell line was cultured according to the recommended conditions provided by the 
ATCC. WM115 cells were grown in Minimum Essential Media-Alpha (MEM-α)  
(Invitrogen) supplemented with 10% foetal calf serum (FCS) and 1% penicillin-streptomycin 
(Gibco, NY, USA). The JL-PRE and EH-POST cell lines were grown in Dulbecco's Modified 
Eagle Medium (DMEM) (Invitrogen) supplemented with 10% foetal bovine serum (FBS) and 
1% penicillin-streptomycin (Gibco, NY, USA). All cell lines were grown in filter-cap tissue 
culture flasks and incubated under standard conditions with 5% CO2, 21% O2 at 37°C in a 
humidified atmosphere.  
 
Cells were frozen in 1 mL of their respective culture medium with 5% sterile-filtered DMSO 
(dimethyl sulfoxide). DMSO prevents ice-crystal formation during freezing. Cells stocks were 
made throughout this project and frozen at -80°C before being relocated into liquid nitrogen 
cylinders for long-term storage until required. 
 
3.2.1.2 Cell Culture Procedure 
For all cell lines, a general protocol for adherent human melanoma cell lines was followed. To 
grow an initial culture, a single 1 mL frozen stock of respective cells was thawed from liquid 
nitrogen storage and seeded in a 75 cm2 filter-cap adherent tissue culture flask (Greiner Bio 
One) with 14 mL of respective culture medium (a total volume of 15 mL). Cells were incubated 
under standard conditions until they reached >85% confluency. 
 
As the nature of adherent cell cultures requires trypsinisation to dissociate the cells from the 
culture vessel, cells were treated with the proteolytic enzyme trypsin during cell passage (79). 
Following trypsinisation cells were passaged to a 175 cm2 tissue culture flask with 23 mL 
culture medium (a total volume of 24 mL).  Once cultures reached >85% confluency, cells 
were ready to be used for transfection experiments, frozen for long-term storage or removed 
for DNA/RNA extraction.  
 
The duration of time to reach confluency in 175 cm2 flasks varied by cell lines, ranging from 
three to six days. The morphology and condition of the cells was monitored daily by 
microscopy to ensure the viability of the cells at every stage in the cell culture process. 
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3.2.2 First Transfection Experiments 
Initial transfection conditions were based on previous experiments (Chatterjee Group, Smith 
et al., manuscript under revision, University of Otago) for the demethylation of melanoma cell 
lines with the TET1CD effector protein. The method of transfection used in this project was a 
transient transfection using lipofection. Lipofection transfections are lipid-based and work by 
forming a lipid complex with the DNA in order to interact with the cell membrane. Separately, 
a reaction is performed in which positively charged liposomes surround the DNA to be 
transfected and form a liposome-DNA complex. This complex is then introduced to the cells 
and is taken up through endocytosis. 
 
3.2.2.1 Preparation of DNA 
The total amount of DNA used in each transfection reaction (per well) was 1500 ng in a 1:1:1 
ratio for each plasmid. For example, 500 ng of the dCas9-SunTag plasmid is combined with 
500 ng of the gRNA_472- plasmid and 500 ng of the DNMT3A plasmid. Each plasmid 
concentration was re-checked using the Nanodrop and was diluted to the required 


















Figure 3.1. Initial Transfection Plan for WM115 Cell Line. Transient transfection plan using eight 
combinations of triple-plasmids. Each combination was done in duplicate, including the negative 
control. Here, IM refers to the inactivate control for DNMT3A. Single component transfections were 











































































Following preparation of the DNA combinations, the lipofectamine lipid complexes were 
produced based on previous optimisation experiments (72). First, 8 μL of Lipofectamine 3000 
reagent (Invitrogen) and and 5 μL of P3000 reagent (Invitrogen) were diluted in 125 μL of 
Opti-MEM Serum Free Medium (Invitrogen) each. Next, 133 μL of Lipofectamine 3000 
reagent and 130 μL of P3000 were added to each respective DNA combination and incubated 
for 15-20 minutes at room temperature to allow the formation of DNA-lipid complexes. 
Following incubation, each respective DNA-lipid complex was added to separate well of a 6-
well plate, as illustrated above in Figure 3.1. Approximately 5.0 × 105 cells were trypsinised 
and resuspended in respective culture medium and added to each well containing the DNA-
lipid complex. This is known as a reverse transfection technique. Culture medium was then 
added to make a total of 3 mL per well. Each 6-well plate was then incubated under standard 
conditions for 6 hours to allow lipofection transfection. 
 
3.2.2.3 Cell Recovery  
Following the exposure to the DNA-lipid complexes to allow transfection for 6 hours, 
transfection reagents were removed from each well and replaced to allow cells to recover. Cells 
were washed with DPBS (Dulbecco’s Phosphate Buffered Saline) to remove any residual 
reagents, and 3 mL of fresh respective culture medium was added to each well and re-incubated 
under standard conditions until 72-hours post-transfection. 
 
3.2.2.4 Cell Preparation for FACS and Flow Cytometry 
At 72-hours post-transfection, culture medium was removed from each respective well, cells 
were washed with DPBS and trypsinised. Cells were then resuspended and stained with the 
LIVE/DEAD Fixable Near-IT Dead Cell Stain Kit (Invitrogen), as per the manufacturer’s 
protocol, to differentiate between live and dead cells during flow sorting. Cells were then 
resuspended in 250 μL sterile autoMACS buffer (1× DPBS, 1% FCS and 2 mM EDTA 
(ethylene-diamine-tetra-acetic acid)). Each sample was flow-sorted using the BD FACSAria 
Fusion (BD Biosciences) by Dr Michelle Wilson (Department of Microbiology, University of 
Otago). Each sample was sorted based on positivity for all transfected plasmids indicated by 
their expression of a fluorophore (mTagBFP, sfGFP and TagRFP657) through a respective 
channel detectable by the BD FACSAria Fusion. 
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Transfection efficiency experiments (Section 3.2.4) were analysed using the BD Gallios Flow 
Cytometer (Department of Pathology, University of Otago). 
 
For each cell line, a negative control and a positive control sample was included. The negative 
control samples were used to establish accurate FACS gating parameters for each respective 
population of cells. An example of the gating established using the negative control samples is 
shown in Figure 3.2.  The negative control sample contained approximately the same number 
of seeded cells as the transfected samples. It was exposed to the same reagents and conditions 
as the transfected samples; however, no DNA was transfected.  
 
The positive control sample was included to establish transfection efficiency, as well as 
improve gating for the BFP and GFP channels due to spectral overlap. The cells in the positive 
control sample were transfected with strongly expressing GFP plasmid (pEGFP-C1) obtained 
from Clontech (catalogue #6084-1). The LIVE/DEAD Fixable Near-IT Dead Cell Stain Kit 
(Invitrogen) was also used for accurate flow cytometry gating for this experiment, as per the 
manufacturer’s protocol.  
 
3.2.3 FACS Gating 
Cells were first gated based on SSC and FSC to exclude any debris. Next, using the negative 
control sample, these cells were gated for the live-dead stain used in these experiments (FSC-
A and APC-Cy7-A) to isolate the population of live cells, as shown in Figure 3.2A. The next 
procedure was to gate the live cell population based on positivity for each of the three 
fluorophores in their respective channels; mTagBFP is fluorescent in the DAPI channel, sfGFP 
in the FITC channel and TagRFP657 in the APC channel, as shown (Figure 3.2B). The pEGFP 
transfected cells (positive control), demonstrated fluorescence in the DAPI channel and were 
to compensate for spectral overlap between mTagBFP and sfGFP. Other single gating 
parameters were based on previous unpublished experiments using single-plasmid transfected 
cells; for example, cells transfected with only gRNA_472-TagRFP657 (Chatterjee Group, 
University of Otago). Data was analysed using FlowJo® 10.4.2 software (FlowJo, LLC). The 






















Figure 3.2. Establishment of FACS Gating using WM115 Negative and Positive Control Samples. 
(A) The example shown here illustrates the gating process based on a negative control sample. The total 
cell population can be accurately distinguished from any remaining debris in the sample using the FSC-
A and SSC-A assessments. Additionally, the live cell population can also be distinguished from dead 
or apoptosing cells as illustrated in this example. (B) Shown here is the establishment of gates for each 
of the three respective fluorophores with the added accuracy of including positive GFP-expressing 
control cells. As shown, there is a clear population of GFP expressing cells in the FITC-A channel, 
highlighted by the P7 gate. In addition to fluorescing in the FITC-A channel, due to cross talk between 
channels, a few cells appear in the DAPI-A channel as well, highlighted by the P6 gate.  Excluding 
these cells from the gate allows for the accurate identification of true BFP expressing cells. 
 
 
3.2.3.1 Spectral Overlap Between BFP and GFP 
The BD FACS Aria Fusion (Department of Microbiology and Immunology) was capable of 
exciting and detecting the BFP fluorophore with the violet laser (405 nm). However, this is a 
suboptimal excitation laser for the mTagBFP fluorophore, and the optimal UV excitation 
laser was unavailable and the implications of this are discussed further in Chapter 5, Section 
5.1.2.1.1. 
  
Total Cell Population Live Cell Population A 
Cel
Gating for Fluorophore-Positive Cells B 
Cel
RFP BFP GFP 
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3.2.4 Transfection Efficiency Experiment 
A common method of determining the transfection efficiency of a cell line is to transfect the 
cell line with a plasmid encoding for a fluorescence protein. The percentage of cells expressing 
the fluorescence protein can then be visualised using fluorescence microscopy and quantified 
using flow cytometry. One of the cell lines used in this project, JL-PRE, had not been used for 
transfection experiments prior to the commencement of this work. Therefore, a transfection 
efficiency experiment was performed to determine its viability for further triple-plasmid 
transfection experiments. JL-PRE cells were transfected with the high-expressing GFP 
plasmid, (pEGFP-C1) under the same transfection conditions described in Section 3.2.2. 
Following 48 hours of transfection, cells were visualised using fluorescence microscopy and 
subsequently quantified using the BD Gallios Flow Cytometer (with the assistance of Rob 
Weeks, Department of Pathology, University of Otago). 
 









3.3.1 Cell Line Viability 
Both WM115 and JL-PRE cell lines were observed to grow well, and cultures were healthy as 
observed by light microscopy. The EH-POST cell line was very slow growing and appeared 
unhealthy despite maintaining appropriate cell culture conditions. It was therefore not viable 
for transfection experiments, and transfection experiments proceeded only with WM115 and 
JL-PRE. 
 
3.3.2 Confirmation of Viability of JL-PRE Cell Line for Transfection 
3.3.2.1 Qualitative Analysis of Fluorescence by Microscopy 
Following transfection of JR-PRE with pEGFP-C1, cells were visualised and imaged using an 
inverted microscope to confirm the presence of GFP fluorescence (Figure 3.3.). Two technical 
duplicates were performed for both the negative control cells and the transfected cells. As seen 
below, fluorescence can be observed in the pEGFP-C1 transfected cells with a GFP filter, but 


















Figure 3.3. Confirmation of EGFP Fluorescence in JL-PRE cell Line. Images of transfected JL-
PRE cells acquired by an inverted microscope at magnification 20x after 48 hours of transfection. 
Images of each respective sample are of the same microscope frame. (A) Negative control cells imaged 
using standard white light and (B) Negative control cells imaged using a GFP filter to visualise GFP  
fluorescence. (C) pEGFP-C1 transfected cells imaged using a standard white light and (D) pEGFP-C1 
transfected cells imaged using an appropriate filter to visualise GFP fluorescence.  
Negative Control 





3.3.2.2 Quantitative analysis of fluorescence by flow cytometry 
In addition to analysis by microscopy, JL-PRE cells transfected with pEGFP-C1 DNA were 
also analysed by flow cytometry. Illustrated in Figure 3.4 below, JL-PRE cells show 28.96% 






























Figure 3.4. Confirmation of EGFP Fluorescence in JL-PRE Cell Line. (A) Negative control cells 
treated with transfection reagents but no DNA, showing no fluorescence in the GFP C+- gate.  (B)  Cells 
transfected with pEFGP-C1 DNA  showing fluorescence in the GFP C+- gate. 28.96% of live cells are 
expressing GFP. Figures were generated with the Kaluza Analysis Software (Version 2.1).  




All 2,220 100.00 % 
C - - 1,543 69.50 % 
C - + 29 1.31 % 
C + - 643 28.96 % 
C + + 5 0.23 % 




All 7,050 100.00 % 
C - - 7,035 99.79 % 
C - + 14 0.2 % 
C + - 1 0.01 % 
C + + 0 0.00 % 
A Control Cells B GFP Transfected Cells 
C - + Live/Dead Positive, GFP Negative  C + +  Live/Dead Positive, GFP Positive 
C - - Live/Dead Negative, GFP Negative  C + - Live/Dead Negative, GFP Positive 
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3.3.3 Initial Transfections of WM115 Cell Line 
The initial transfections of the WM115 cell line yielded a very small amount of triple-positive 
transfected cells. The total number of cells acquired from three initial experiments for each 
plasmid combination is listed below in Table 3.2. A variable number of cells was observed for 
each combination, indicating possible differing transfection efficiencies across plasmid 
combinations.  
 
Table 3.2. Total Number of Cells Collected from Initial Transfection of WM115 for Each 
Plasmid Combination Across Three Experiments. 
 
Plasmid Combination Cells Collected 
DNMT3A, 10x, gRNA_472- 1 
DNMT3A, 10x,  gRNA_474+ 15 
DNMT3A, 5x, gRNA_472- 0 
DNMT3A, 5x, gRNA_474+ 0 
DNMT3A_IM, 10x, gRNA_472- 6 
DNMT3A_IM, 10x, gRNA_474+ 8 
DNMT3A_IM, 5x, gRNA_472- 3 
DNMT3A_IM, 5x,  gRNA_474+ 3 
 
3.3.4 Modified Transfection of WM115 Cell Line 
The initial transfection of WM115 cells yielded a low number of triple-transfected cells, 
therefore, the transfection strategy was modified. The goal was to increase the number of triple-
transfected cells by scaling up the number of cells transfected.  
 
Initial transfections included two different gRNA molecules (gRNA_474+ and gRNA_472) as 
well as two different versions of the CRISPR-dCas9-SunTag plasmid (5x GCN4 and 10x 
GCN4), as described in Chapter 2, Section 2.1.2. In addition to the active DNMT3A plasmid 
and the inactive control (DNMT3A-IM), this makes for eight different combinations. 
Transfections were performed in three 6-well plates, with two wells per each combination. It 
was predicted that if the number of wells was increased, then that would increase the number 
of potentially triple-transfected cells. To make this practically possible, it was decided to 
simplify the number of plasmid combinations. According to previous experiments (Chatterjee 
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Group, University of Otago), the gRNA_472- was more efficient in methylation editing than 
gRNA_474+, and the 10x-dCas9 plasmid was also more efficient than the 5x-dCas9 plasmid 
at demethylating melanoma cell lines. Therefore, the next set of experiments proceeded with 
only 10x-dCas9 and gRNA_472.  
 
There were 13 triple-transfected cells for the DNMT3A group and 11 triple-transfected cells 
for the DNMT3A-IM group. The transfection efficiency was found to be 22.81% for the 
positive control sample. The transfection efficiency is discussed in more detail in Chapter 5, 
Section 5.1.1. A greater number of triple-transfected cells was able to be acquired through the 
modified transfection strategy for WM115, although no statistical significance can be drawn 
as the modified transfection experiment was only performed once due to the significant time 
restraints of this project.  
 
3.3.4.1 Preparation of DNA 
Additionally, the ratio of plasmid DNA was thought to potentially influence the uptake of all 
three plasmids. Since the plasmids are of difference sizes and therefore different molecular 
weight (refer to Chapter 2, Table 2.1), adding a 1:1:1 ratio of each plasmid would result in a 
larger proportion of the smaller-sized plasmids. Therefore, to achieve molar equivalent 
amounts of each plasmids in each well, the ratio was adjusted to 2:1:1.2 for the dCas9-10x, 
gRNA_472- and DNMT3A/DNMT3A-IM plasmids respectively.  
 
Cell recovery (Section 3.2.2.3), cell preparation for FACS (Section 3.2.2.4) and FACS gating 
(Section 3.2.3) remained the same as in the initial transfection protocol.  
 
3.3.5 Transfection of JL-PRE Cell Line 
The modified transfection strategy was also performed on the JL-PRE cell line. However, 
instead of three six-well plates, only two six-well plates were used due to insufficient number 
of cells being available on the day of transfection. Only 6 triple-transfected cells for the 
DNMT3A group and 6 triple-transfected cells for the DNMT3A-IM group were collected by 
flow sorting. This experiment was unable to be repeated due to the significant time constraints 
of this project. 
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Overall, this chapter shows the successful transfection and sorting of triple-transfected cells in 
the WM115 and JL-PRE cell lines.   
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3.4 Statement of Contribution 
FACS sorting was performed by Dr. Michelle Wilson (Department of Microbiology, 
University of Otago). Flow Cytometry to test transfection efficiency was performed with the 
assistance of Rob Weeks (Department of Pathology, University of Otago). I have performed 
all the further experiments and subsequent analysis including figure generation. 
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4.1.1  Principles of Bisulfite Conversion 
Treating DNA with sodium bisulfite is a very effective technique for analysing the methylation 
status of cytosine residues within the genome (80). Bisulfite conversion of genomic DNA 
stimulates unmethylated cytosine to hydrolytically deaminate and convert to uracil, while 
methylated cytosines resist treatment to bisulfite and remain unconverted (80-82). 
Subsequently, comparing bisulfite-converted DNA and unconverted DNA allows for 
methylation analysis at a single nucleotide resolution. 
 
4.1.2  Illumina iSeq Sequencing 
Analysis of DNA methylation was performed using the Illumina iSeq platform, a next-
generation sequencing platform that allows for the high-throughput analysis of multiple genes 
within a single run. In combination with bisulfite conversion of genomic DNA, the iSeq 
platform allows for detailed methylation-specific sequencing and analysis of the DNA 
methylome. The 285 bp EBF3 amplicon and 58 bp target region interrogated by the iSeq are 








Figure 4.1. Genomic Map of Amplicon and Target Site within EBF3 Promoter Region. Illustrated 
here is a simple schematic showing the region within the EBF3 promoter that is investigated throughout 
this project. Labelled is the 285 bp region consisting of 34 CpG sites, of which CpG sites 10-18 (nine 
CpG) sites represent the 58 bp target region originally described by Chatterjee et al. (2017) (27). Also 
labelled is the EBF3 transcription start site (TSS) and the direction of transcription is shown (black 




The work described in this Chapter aimed to assess the DNA methylation status of the EBF3 
promoter region in cells transfected with the DNMT3A methylation editing system. This was 




4.2   Materials and Methods 
4.2.1 Sample Preparation for Illumina iSeq Sequencing 
The sections below detail the steps involved in preparing samples for Illumina iSeq 
Sequencing. 
 
4.2.1.1 Bisulfite Conversion of DNA 
Due to low numbers of FACS-collected WM115 and JL-PRE cells, all available FACS-
collected cells were combined to for each respective cell line. Cell lysate volumes were reduced 
using a vacuum centrifuge, prior to bisulfite conversion with the EZ DNA Methylation-Direct 
Kit (Zymo Research), and bisulfite conversion was carried out according to the manufacturer’s 
protocol. The total number of FACS collected cells from the transfection of JL-PRE is also 
listed in Table 4.1.  
 
Table 4.1 Combined Total Number of FACS Collected Cells for Bisulfite-Specific 
Analysis for Each Cell Line. 
 
Cell Line Edited Cells Inactive Control 
FACS  
Negative Control 
WM115 29 23 10,000 
JL-PRE 6 6 10,000 
 
For the unedited WM115 and JL-PRE samples, a large number of cells were harvested from 
these cell cultures, and the AllPrep DNA/RNA Mini Kit (Qiagen) was used to isolate genomic 
DNA and RNA simultaneously, according to the manufacturer’s protocol. This kit allows for 
high quality DNA and RNA to be isolated from the same sample, and is therefore ideal for 
downstream DNA and RNA analysis. However, the extracted RNA was not used any further 
in this project. Further, the EZ DNA Methylation-Gold Kit (Zymo Research) was used for 
bisulfite conversion of extracted DNA from these samples, as per the manufacturer’s protocol. 
 
4.2.1.2 Primers 
Primers specific to the 285 bp region of EBF3 promoter were previously designed before the 
commencement of this project. The primer sequence, including the Illumina adaptor sequences, 
are shown below in Table 4.2. 
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Table 4.2. Bisulfite-Specific Primers Designed to the EBF3 Promoter 
Primer Name Primer Sequence (5’ à 3’) 
EBF3_993_F ACGACGCTCTTCCGATCTGGAGTTAATTGTTTTAAAAATTAAG 
EBF3_993_R CGTGTGCTCTTCCGATCTCTCTTAACAAAAAAATACCTAAAAC 
Illumina adaptor sequences are highlighted in bold. 
 
4.2.1.3 Amplicon-Specific PCR 
PCR amplification was performed for each sample using the EBF3_993_F and EBF3_993_R 
primer pair. This PCR amplifies the 285 bp EBF3 region to produce a 321 bp amplicon after 
the addition of the respective forward and reverse primers. PCR was performed using KAPA 
HiFi DNA Polymerase in a total reaction volume of 10 μL. Reagents for the reaction are listed 
in Table 4.3. A touch-down PCR amplification protocol was used as detailed in Table 4.4.  
 
Table 4.3. PCR Reaction Reagents for EBF3 Promoter Amplification. 
Reagent Volume 
Kapa HiFi Polymerase (2x Ready Mix) 5.0 μL 
EBF3_993_F (10 μM) 0.5 μL 
EBF3_993_R (10 μM) 0.5 μL 
MQ H2O 3.0 μL 
Bisulfite-Converted DNA 1.0 μL (50ng) 















Table 4.4. Touch-Down PCR Protocol for EBF3 Promoter Amplification. 
Protocol 
Step 1 95°C 3 minutes 
Step 2 95°C 30 seconds 
Step 3 60°C à 55°C (0.5°C/cycle) 30 seconds 
Step 4 72°C 30 seconds 
Step 5 GOTO Step 2 Repeat x19 
Step 6 94°C 30 seconds 
Step 7 50°C 30 seconds 
Step 8 72°C 30 seconds 
Step 9 GOTO Step 6 Repeat x34 
Step 10 72°C 5 minutes 
Step 11 12°C Infinite Hold 
 
Successful amplification and the absence of contamination was confirmed by visualisation on 
a 2% agarose gel. 
 
4.2.1.4 Serial Dilutions of DNA and PCR Amplification 
As an initial experiment, serial dilutions of one DNA sample from the WM115 cell lines was 
performed in order to confirm the correct primers and amplification of the expected products, 
as well as confirm the amount of DNA that could be expected to be amplified with the touch-
down PCR protocol (Table 4.4). This is relevant to selecting the optimal touch-down PCR 
protocol, as well as to the amplification of very small amounts of DNA samples. The same 
reagents listed in Table 4.3 were used for this experiment, and six 1:5 serial dilutions were 
performed on a 50 ng/μL sample of DNA. 
 
4.2.1.5 Bead Purification and Dilution 
Amplified product was then purified using AMPure XP magnetic beads (Beckman Coulter) to 
remove residual primers and excess reagents. For the appropriate size selection of the target 
amplicon, a 1:1 volume ratio of beads to product was used for each respective sample. During 
bead purification, samples were washed twice with freshly aliquoted 80% ethanol, air-dryed 
and resuspended in 20 μL TE Buffer. 
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Each purified sample was then quantified using the Qubit High Sensitivity 1x dsDNA Kit 
(Invitrogen) and the Qubit Fluorometer 4 (Invitrogen). Based on the obtained quantifications, 
each sample was then diluted to a concentration of 1 ng/μL. 
 
The ratio of AMPure XP magnetic beads was confirmed prior to use on samples, by purifying 
500 ng of a 1 kb DNA Plus Ladder and a 100 bp DNA Plus Ladder. 
 
4.2.1.6 Sample Indexing PCR 
Via second round of PCR, each sample was indexed with a unique pair of Illumina forward 
and reverse adaptor sequences. Reagents for the reaction are listed in Table 4.5 below. The 
amplicon will be 418 bp in size after indexing. The PCR protocol used in also detailed in Table 
4.6. Successful sample indexing was confirmed by visualisation on a 2% agarose gel. 
 
Table 4.5. Reagents for Illumina Adaptor PCR Reaction. 
Reagent Volume 
Kapa HiFi Polymerase (2x Ready Mix) 5.0 μL 
10 μM Forward Primer 0.25 μL 
10 μM Reverse Primer 0.25 μL 
MQ H2O 2.0 μL 
Amplified DNA 2.0 μL 
Total 10.0 μL 
 
Table 4.6. PCR Protocol for Illumina Adaptor Ligation 
Protocol 
Step 1 95°C 2 minutes 
Step 2 95°C 20 seconds 
Step 3 58°C 20 seconds 
Step 4 72°C 20 seconds 
Step 5 GOTO Step 2 Repeat x10 
Step 6 72°C 40 seconds 




4.2.1.7 Library Multiplexing and BioAnalyser Assessment 
Following confirmation of sample indexing, all samples were multiplexed into a single, 
combined library. The combined library was further bead purified using AMPure XP beads, as 
described in Section 4.2.1.4.  
 
The multiplexed library was then quantified using the Qubit High Sensitivity dsDNA Kit as 
previously described, and a sample of the combined library was accordingly diluted to 1.0 
ng/µL for assessment on the BioAnalyser 2100 High Sensitivity DNA Assay. 
 
4.2.1.8 Final Library Dilutions 
In accordance with the BioAnalyser assessment and the Qubit quantifications, the final library 
was diluted to 50 uL (4nM) prior to iSeq Sequencing.  
 
4.2.2 Illumina iSeq Sequencing  
The multiplexed library was sequenced on the Illumina iSeq Sequencer (Department of 
Anatomy, University of Otago), performed by Rob Weeks (Department of Pathology, 
University of Otago). Based on the unique Illumina index sequences for each respective 
sample, sequencing data was demultiplexed and made available for analysis. 
 
4.2.2.1 Analysis of iSeq Sequencing Data 
Multiple bioinformatic steps are required for processing of raw iSeq sequencing data for DNA 
methylation analysis. The approach described here is based on an existing bioinformatic 
framework established by the Morison Laboratory Group (Department of Pathology, 
University of Otago). The steps described in this section are performed automatically using 
macOS Mojave. The full script is included in Appendix B.  
 
The first step in the data processing pipeline is the joining of pair-ended sequencing reads using 
PEAR (Paired-End reAd mergeR). Designed by Zhang et al. (2014) (83), PEAR compares all 
possible read overlaps and joins corresponding reads to form the entire 285 bp EBF3 amplicon. 
PEAR is also capable of using statistical tests to reduce the possibility of false-positive merging 
of reads (83). Merged sequencing reads are then quality assessed by FastQC (Babraham 
Bioinformatics), which ensures that sequencing outputs of a poor quality are identified and 
removed from the analysis. 
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The Illumina adaptor index sequences are then removed from each of the merged reads using 
Trim Galore! (Version 0.5.0, Brabraham Bioinformatics). The FastQC is then run again for 
quality assessment. Next, the FASTX-ToolKit (Hannon Lab, 2014) is used to convert the 
sequencing reads into a readable format for BiQ Analyser HT processing. The reads are first 
converted from FASTQ to FASTA format, and then the FASTX Barcode Splitter is used to 
demultiplex sequences according to the respective primer sequence used for initial 
amplification (Refer to Section 4.2.1.3). This ensures that all reads that progress to the BiQ 
Analyser HT are true amplimers of EBF3 and any incorrect products are discarded. 
 
Finally, the BiQ Analyser HT package (84) aligns all processed reads to the specified genomic 
reference sequence, and establishes binary methylation data (either methylated or 
unmethylated) for each available aligned read. This data is then outputted in multiple different 
formats including heat maps and pearl necklace plots. These output files are then used for the 
further processing of methylation data. 
 
4.2.2.1.1 Further Processing 
Using the output files from the BiQ Analyser HT analysis, I imported binary methylation data 
into Microsoft® Excel (version 16.41) and Prism 8.4.3 (GraphPad) for further analyses and the 
generation of figures. The average methylation per CpG site was calculated based on the 
average of all processed reads per sample. The average methylation across the target region 
and the entire amplicon is calculated based upon the averge of all CpG sites in each respective 
region of the amplicon.  
 
4.2.2.1.2 Statistical Analysis 
No independent replicates per sample were available. Therefore, no statistical analyses were 
performed on this data, as no significant conclusions could have been inferred from any 







4.3   Results 
4.3.1 Sample preparation for iSeq Sequencing  
4.3.1.1 Confirmation of AMPure XP Magnetic Beads 
The ratio of AMPure XP magnetic beads was confirmed by purifying 250 ng of a 1 kb DNA 
Plus Ladder and 250 ng of a 100 bp DNA Plus Ladder. Figure 4.2 below shows successful 















Figure 4.2. Agarose Gel Images Confirming Successful AMPure XP Magnetic Beads Purification 
with 1 kb Plus DNA Ladder and 100 bp DNA Ladder. Shown here is the confirmation of successful 
sample indexing visualised on a 2% agarose gel. (A) Lane 1 shows 0.5 µg of unpurified 1 kb Plus DNA 
ladder, and Lane 2 shows 0.5 µg of bead-purified 1 kb Plus DNA ladder. The absence of the 100 bp 
band is indicated by the red arrow. (B) Lane 1 shows 0.5 µg of unpurified 100 bp DNA ladder, and 
Lane 2 shows 0.5 µg of bead-purified 100 bp ladder. The absence of the 100 bp band is indicated by 
the red arrow. 
 
 
4.3.1.2 Confirmation of Amplification with Bisulfite Specific Primer and Dilutions 
WM115 sample DNA was successfully amplified using the EBF3 bisulfite-specific forward 
and reverse primers. Four out of six of the diluted samples were visualised by gel 
electrophoresis (Figure 4.3), confirming that amounts of DNA as low as 0.08 ng (80 pg) can 
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Figure 4.3. Agarose Gel Images Confirming Successful Amplification and Serial Dilutions of 
WM115 DNA. Shown here is the confirmation of successful amplification and 1:5 serial dilutions of 
50 ng/μL of WM115 DNA visualised on a 2% agarose gel. Lane 1 includes 0.5 μg of 1 kb Plus DNA 
Ladder for sizing reference. Lane 3 includes undiluted DNA. Samples which have successfully been 
amplified are 321 bp in size. Lanes 4 to 9 include the serially diluted samples of 10 ng/μL, 2. ng/μL, 
0.4 ng/μL and 0.08 ng/μL, respectively. A negative control sample containing the master mix, but no 
DNA was included in Lane 11. No product can be visualised in this negative control sample, indicating 
the absence of contamination. Primer dimer is present in small amounts within each sample, as indicated 
by the faint bands at less than or equal to 100 bp in size. This is a consequence of primer dimerisation 
during PCR amplification. 
 
 
4.3.1.3 Confirmation of Amplicon-Specific PCR 
After PCR amplification, 3.0 µL of each sample was electorophoresed through 2% agarose gel. 
The size of the EBF3 promoter amplicon is 285 bp, and with the addition of bisulfite-specific 
primers the size is expected to be 321 bp. The presence of the correct-size bands visualised by 
gel electrophoresis (Figure 4.4) indicates that the DNA was both successfully bisulfite 
converted and successfully amplified during the PCR reaction. Primer dimer was present in 
small amounts within each sample. This is a consequence of primer dimerisation during PCR 
amplification and was removed via sample purification. 
 
No bands were visualised in the JL-PRE edited and JL-PRE inactive control samples. This is 
likely due to the low number of cells originally present in these samples. However, these 
samples were not discarded, as it was possible that there may have been amplified DNA present 

























Figure 4.4. Agarose Gel Image Confirming Successful Amplicon-Specific PCR. Shown here is the 
confirmation of the amplicon-specific PCR reaction on a 2% agarose gel. Lane 1 includes 0.5 μg of 1 
kb Plus DNA Ladder for sizing reference. Samples which have successfully been amplified are 321 bp 
in size (indicated by the blue arrow). Samples which may have failed to amplify are circled in red. A 
negative control sample containing the master mix but no DNA was included in Lane 12. No product 
can be visualised in this negative control sample, indicating the absence of contamination. Primer dimer 
is present in small amounts within each sample, as indicated by the faint bands.  
 
4.3.1.4 Quantification of Amplified Product 
The JL-PRE edited sample and inactive control sample were quantified to 0.764 ng/µL and 
3.86 ng/µL respectively (Table 4.7). Although these are low concentrations, it is an indication 
that there is amplified product in the samples, and so the samples were not discarded.  
 
Table 4.7. Qubit Quantification of Amplified Products. 
Sample Name Concentration (ng/µL) 
WM115 Unedited 37.4 
WM115 Edited 9.9 
WM115 Inactive Control 40.6 
WM115 FACS Negative Control 39.6 
JL-PRE Unedited 36.6 
JL-PRE Edited 0.764 
JL-PRE Inactive Control 3.86 










Amplicon-Specific PCR Product Negative Control 
(No DNA) 
1 2 3 4 5 6 7 8 9 10 11 12 
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4.3.1.5 Confirmation of Successful Sample Indexing Prior to iSeq Sequencing 
Following bead purification and quantification of the successful amplicon-specific PCR 
products, diluted samples were diluted to 1 ng/µL and 2 ng was used for the second round of 
PCR amplifications. Each sample was indexed with a pair of unique Illumina forward and 
reverse adaptor sequences via a second round of PCR. The expected size of the product after 
indexing was 418 bp. 
 
Successful indexing of the samples was observed via visualisation on a 2% agarose gel as 
shown in Figure 4.5. Consistent with the agarose gel image of the amplicon-specific PCR 
(Figure 4.4), no bands were visualised in the JL-PRE active and JL-PRE inactive control 
samples, however the samples were not discarded. Primer dimer was present in small amounts 
within most samples and in larger amounts within some samples. This is a consequence of 




















Figure 4.5. Agarose Gel Image Confirming Successful Sample Indexing. Shown here is the 
confirmation of successful sample indexing visualised on a 2% agarose gel. Lane one includes 1.0 µg 
of 1 kb Plus DNA Ladder for sizing reference. Lane two includes a 321 bp purified sample from the 
amplicon-specific PCR reaction (indicated by the blue arrow) to compare and visualise the expected 
increase in product size during sample indexing. Successful sample indexing is indicated by an increase 
in product size to 418 bp. All visualisable samples have increased to the correct size (indicated by the 
red arrow). No product is visualised in lanes 7 and 8 (circled), however samples were not discarded. 
Primer dimer is present in small amounts within most samples and in larger amounts within some 
samples, as indicated by presence of smaller-sized bands.  
 
 









1 2 3 4 5 6 7 8 9 10 11 
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4.3.1.6 BioAnalyser Assessment 
The combined library was then quantitatively and qualitatively assessed using the BioAnalyser 
2100 High Sensitivity DNA Assay (Figure 4.6) prior to final library dilutions for iSeq 
sequencing. The EBF3 amplicon with the Illumina indexes is expected to be 418 bp in size, 
and the average size reported on the BioAnalyser assessment was 419 bp. 
 
The compiled library was therefore observed to be approximately of the expected size and of 
a relatively good purity as shown in Figure 4.6. Two products of smaller peaks are also 
observed on the BioAnalyser assessment, and these are likely to be primer dimers suggesting 
that not all primer dimers were removed during bead purification. Nevertheless, the product is 
observed to be relatively pure and of the expected size. 
 
 
Figure 4.6. BioAnalyser 2100 Electropherogram Assessment of the Compiled EBF3 Library. 
Shown is the bioanalyser assessment of the purity and size of the compiled library preparation. This 
sample contains a total of eight transfected and non-transfected samples. The EBF3 amplicon with the 
addition of bisulfite specific primers and Illumina indexes is expected to be 418 bp in size. Here, the 
product is assessed to be 399 bp in size, with an average reporting of 419 bp in size.  Two smaller peaks 
are also present, and these are likely to be primer dimers which were not removed during bead 












4.3.2 Illumina iSeq Sequencing 
This section includes the results obtained from the analysed methylation-specific iSeq 
sequencing of the EBF3 promoter region in the transfected cell lines WM115 and JL-PRE. 
Sequencing was performed on a total of eight samples, and all samples were successfully 
sequenced. Samples include unedited cells, FACS negative control cells, inactive control cells 
and edited cells for each cell respective line. The quality of the run was very good, as were the 
number of reads present for each sample.  
 
The results include the average DNA methylation level analysed across both the target region 
(nine CpG sites, 58 bp in length) as well as the entire EBF3 amplicon (34 CpG sites, 285 bp in 
length). A schematic of the entire EBF3 amplicon and the target region is illustrated in Figure 
4.1. 
 
Only one replicate of each cell line was available for analysis in this project. As such, no 
statistical analyses have been performed on these results, as no significant conclusions could 
have been inferred from any statistical comparisons. These results are further discussed in 
Chapter 5, Section 5.1.3. 
 
4.3.2.1 Baseline DNA Methylation in WM115 
Baseline levels of DNA methylation within the EBF3 amplimer was assessed with unedited 
WM115 cell line sample. The average level of DNA methylation across the 9 CpG target region 
was found to be 58.0%. The methylation status of this cell line was found to be comparable to 
unpublished RRBS data (Chatterjee Lab Group, University of Otago) which observed an 




















Figure 4.7. Baseline Average DNA Methylation per CpG for Unedited WM115 Cells. Average 
levels of DNA methylation are shown for each CpG site within the EBF3 amplicon. Values indicated 
using orange bars correspond to the nine CpG sites found within the 58 bp target region originally 
described by Chatterjee et al. (2017) (27). Values indicated using green bars correspond to the other 
CpG sites found within the remainder of the EBF3 amplimer.  
 
 
4.3.2.2 Baseline DNA Methylation in JL-PRE 
Baseline levels of DNA methylation within the EBF3 amplimer was assessed with unedited 
cell line samples. The average level of DNA methylation across the 9 CpG target region was 
found to be 7.4%. The methylation status of this cell line was found to be comparable to 
unpublished RRBS data (Chatterjee Lab Group, University of Otago) which observed an 











Figure 4.8. Baseline Average DNA Methylation per CpG for Unedited JL-PRE Cells. Average 
levels of DNA methylation are shown for each CpG site within the EBF3 amplicon. Values indicated 
using orange bars correspond to the nine CpG sites found within the 58 bp target region originally 
described by Chatterjee et al. (2017) (27). Values indicated using green bars correspond to the other 
CpG sites found within the remainder of the EBF3 amplimer.  
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4.3.2.3 Reproducibility of Methylation-Specific iSeq Sequencing 
WM115 baseline levels of DNA methylation within the 285 bp EBF3 amplicon were also 
compared against unpublished independent MiSeq sequencing data (Jim Smith, Chatterjee Lab 
Group, University of Otago, 2017). In Figure 4.9 below, the individual average DNA 
methylation per CpG site for the unedited WM115 sample in this project (2020) is plotted 
against unpublished WM115 data (2017). These were performed near to three years apart on 
cells differing in passage numbers. The results show remarkable similarities, indicating that the 
methylation-specific sequencing assay for the EBF3 amplicon is reproducible. Overall, this 































Figure 4.9. Comparison Between WM115 Average DNA Methylation per CpG Site for 
Independent Sequencing Runs. Average levels of DNA methylation are shown for each CpG site 
within the EBF3 amplicon for two indepdent sequencing runs performed in 2017 and 2020. Values 
indicated in blue correspond to the 2017 data, while values indicated in ble correspond to the 2020 data.   
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4.3.2.4 Comparison of Edited and Unedited WM115 Transfected Cells 
Data from the edited samples and inactive control was available for the cell line WM115. 
Figure 4.10 shows the average DNA methylation values for the unedited samples compared 
against the inactive control sample and the edited sample. For all three samples, average DNA 
methylation is compared across the target region and the entire amplicon. The average 
methylation difference between edited and unedited samples is also labelled. 
 
 
Figure 4.10. Comparison of Average DNA Methylation Levels between Unedited, Edited and 
Inactive Control Samples for WM115 Samples. Average DNA methylation levels assessed via 
Illumina iSeq Sequencing are compared across unedited, edited and inactive control samples for the 
cell line WM115. Each sample is compared for the entire amplicon and target region (nine CpG sites). 
No independent replicates are available for any sample. The percentage of average methylation change 
between unedited and edited samples is shown (Δ).   
 
Though some change in the average DNA methylation level may be present in this cell line, no 
replicates were available for further analysis. An average methylation change of 8.2% observed 
between edited and unedited samples in the target region may be due to selection bias (i.e. 
small number of sorted cells), and more replicates are required to confirm the effectiveness of 
this methylation-editing system.  
 
For the inactive control, the methylation level across the entire amplicon is shown to be similar 
to that of the unedited sample. However, with regard to the target region, a large difference is 




























Δ = 8.2%  Δ = 14.8%  
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and independent replicates of this data will be required before any concrete conclusions can be 
drawn regarding the function of the inactive control. 
 
4.3.2.5 Comparison of Edited and Unedited JL-PRE Transfected Cells 
Data from the edited samples and inactive control was available for the cell line JL-PRE, 
despite the low number of cells prepared for sequencing. Figure 4.11 shows the average DNA 
methylation values for the unedited, the inactive control and the edited samples. For all three 
samples, average DNA methylation was compared across the target region and the entire 




Figure 4.11. Comparison of Average DNA Methylation Levels between Unedited, Edited and 
Inactive Control Samples for JL-PRE Samples. Average DNA methylation levels assessed via 
Illumina iSeq Sequencing are compared across unedited, edited and inactive control samples for the 
cell line JL-PRE. Each sample is compared for the entire amplicon and target region (nine CpG sites). 
No independent replicates are available for any sample. The percentage of average methylation change 
between unedited and edited samples is shown (Δ).   
 
Compared to the WM115 cell line (Figure 4.10), a substantially higher average methylation 
change of 38.0% is observed for JL-PRE between edited and unedited samples in the target 
region. For this particular cell line, the methylation-editing system appears to be more effective, 





























Δ = 38.0%  Δ = 17.4%  
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The change in the average methylation level observed in the inactive control sample is not 
consistent with the unedited samples for either the target region or the entire amplicon.  
Possible reasons for this observation are discussed in Chapter 5, Section 5.1.3.2. 
 
4.3.2.6 Comparison of Unedited Samples to FACS Negative Control Samples for both 
WM115 and JL-PRE Cell Lines  
The FACS Negative Control cells (exposed to transfection reagent, but without DNA) were 
also sequenced and the average DNA methylation levels were analysed for both cell lines. 
These results are expected to be comparable to the unedited baseline average methylation 
levels. Figure 4.12 compares the average methylation levels of each CpG site within the entire 
amplicon for the FACS Negative Control sample and the Unedited sample for both WM115 
and JL-PRE cell lines. 
 
Only minor differences in the average methylation levels at each CpG site for both cell lines 
are observed. These results are expected, as exposure to transfection reagent is not expected to 
alter average DNA methylation levels. These results are however based on only single 

















































Figure 4.12. Comparison of Average DNA Methylation per CpG Site in Unedited Samples and 
FACS Negative Control Sample. Average DNA Methylation levels assessed via Illumina iSeq 
sequencing for the cell lines WM115 and JL-PRE are shown using a line graph for each CpG site within 
the EBF3 amplicon. The values indicated using blue bars correspond to the unedited control samples 
and the values indicated using orange bars correspond to the FACS negative control sample. CpG sites 
10 to 18 represent the target region. No statistical analyses have been performed, as no independent 
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4.3.2.7 Effect of Low Cell Input on iSeq Sequencing  
While the results in Sections 4.3.2.4 and 4.3.2.5 show that the edited samples have increased 
in methylation compared to the unedited controls, multiple independent replicates are required 
before this result can be confirmed. However, single replicate numbers are not the only factor 
impacting the interpretation of these results. A very low number of input cells available for 
DNA extraction and subsequent iSeq sequencing may have also impacted the results and their 
interpretation. This is shown in Figure 4.13 and Figure 4.14 for WM115 and JL-PRE 
respectively.  
 
First shown in Figure 4.13 is the DNA methylation level for the unedited WM115 sample, 
which comes from a large number of total cells. There were 27,600 reads available for this 
sample, a large total number, and as such the pattern of methylation represented in the heatmap 
for this sample shows a reasonable amount of variance.  In contrast, both the edited and inactive 
control samples were sequenced using DNA derived from a very low number of cells (n = 29 
and n = 23, respectively), however they still showed a reasonably high number of reads (n = 
11,809 and n = 23,383). Both the edited and inactive control samples show an identical pattern 
of methylation across their respective reads. It appears likely that a large number of these may 
be a result of the same DNA being amplified from the same cell. 
 
Similarly, the DNA methylation pattern for the unedited JL-PRE sample also comes from a 
large number of cells (Figure 4.14). This resulted in 17,405 reads available for this sample, and 
the heatmap shows a variation among the reads. Both the edited and inactive control samples 
were sequenced using DNA derived from a very low number of cells (n = 6, for both samples). 
Contrastingly to WM115, these samples showed a low number of only 155 reads for the edited 
sample and 204 reads for the inactive control sample. Surprisingly, despite the low number of 
reads and low input of cells, the heatmap shows some variance observed among the reads. 
Without the availability of independent replicates, it is difficult to understand the true 
methylation changes which have occurred in these samples. The implications and biases 

















Figure 4.13. Average DNA Methylation Level per CpG Site for WM115 Samples. The average 
DNA methylation level per CpG site is shown using a bar graph for each of three WM115 samples. The 
nine CpG sites within the 58 bp target region are indicated with orange bars, whilst the remaining CpG 
sites within the EBF3 amplicon are indicated with green bars. The corresponding heatmap image is 
shown alongise each graph. Each heatmap includes 155 randomly selected reads. Each row within the 
heatmap represents an individual sequencing read, whilst each column represents CpG sites 1-34 site 
within the EBF3 amplicon. Unmethylated sites are shown in blue, methylated sites are shown in red 
and uncalled sites are shown in white. 
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Figure 4.14. Average DNA Methylation Level per CpG Site for JL-PRE Samples. The average 
DNA methylation level per CpG site is shown using a bar graph for each of three JL-PRE samples. The 
nine CpG sites within the 58 bp target region are indicated with orange bars, whilst the remaining CpG 
sites within the EBF3 amplicon are indicated with green bars. The corresponding heatmap image is 
shown alongise each graph. Each heatmap includes 155 randomly selected reads. Each row within the 
heatmap represents an individual sequencing read, whilst each column represents CpG sites 1-34 site 
within the EBF3 amplicon. Unmethylated sites are shown in blue, methylated sites are shown in red 
and uncalled sites are shown in white. 
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Overall, this chapter has described the process by which DNA methylation changes were 
investigated at the EBF3 promoter region in two cell lines. It is evident that while some samples 
show promising levels of methylation, particularly the edited sample for the JL-PRE cell line, 
this remains to be an inconclusive result due to these experiments being single-replicates only. 
Multiple independent replicates are required before further conclusions can be drawn. The 




4.4 Statement of Contribution 
The processing of the iSeq sequencing data using macOS terminal was performed by Rob 
Weeks. I prepared the samples and analysis of data including figure generation, with advice 
from my supervisors (Rob Weeks and Dr. Aniruddha Chatterjee). 
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Chapter 5: Discussion, Conclusions and Future Direction 
 
5.1 Discussion and Future Direction 
5.1.1 Transfection with our Methylation-Editing System 
The main observation from the transfection experiments in this project was the low number of 
triple-transfected cells for both cell lines WM115 and JL-PRE. The protocols followed in this 
project were based on previous optimisation experiments for the demethylation system (72).  
 
In the following sections, I discuss possible reasons for this outcome, and potential methods 
that could be employed to increase the transfection efficiency going forward. 
 
5.1.1.1 Effect of Plasmid Size on Transfection Efficiency 
Although FACS collected cells from multiple transfection experiments were combined due to 
low numbers of triple-transfected cells, five total transfection experiments and FACS analysis 
were performed throughout this project (refer to Chapter 3). It was evident during FACS that 
the there was a substantially higher number of positive cells for the gRNA plasmid (7.3 kb) 
compared to both the dCas9 plasmid (14.5 kb) and the DNMT3A plasmid (12.4 kb) (data not 
shown). Although some fluorophores may have different excitement efficiencies detectable by 
FACS, this difference in transfection efficiency for each plasmid is unlikely to be due to 
differences in signal detection. The more likely reason is the size of the plasmids.  
 
Plasmid size is an important factor to consider when discussing transfection efficiency. The 
size of the plasmid does not appear to be directly linked with its ability to enter the cell via 
lipofection, however larger plasmids transit through the cytoplasm at a slower rate which leaves 
them more susceptible to degradation before they are able to reach the nucleus (85, 86).  
 
This is also observed in the initial transfection experiment for JL-PRE, where a 28.9% 
transfection efficiency was observed for transfection with pEGFP-C1 (4.7 kb) (Chapter 3, 
Section 3.3.2.2). Although this was only performed once, a pEGFP-C1 positive control was 
included with each transfection experiment and similar transfection efficiencies of ~30% were 
observed (data not shown). This plasmid is much smaller in size and this is the likely cause for 
the higher transfection efficiency than is observed with the larger plasmids. For these reasons, 
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I am confident that the size of the plasmid is an important factor that has unfortunately hindered 
the transfection efficiency in this project. 
 
It is also worth noting that particular cell lines may have drastically different transfection 
efficiencies compared to other cell lines. For example, with a dCas9-TET1CD (12.6 kb) single 
construct system, Choudhury et al. (2016) observed up to 84.6% transfection efficiency in 
HeLa cells and 56.2% in MCF7 cells. This shows that transfection efficiency can vary 
drastically between cell lines (87). 
 
5.1.1.2 Purity and Quality of Plasmid DNA 
In addition to plasmid size, the plasmid DNA itself can often be a major contributor to the 
toxicity of the cells during the transfection process (88). After DNA extraction, by-products 
such as endotoxins, salts and lipopolysaccharides can remain and cause cell death as well as 
impede the function of lipofectamine’s cationic lipid molecules (89). This in turn can 
significantly affect transfection efficiency. It is therefore crucial that the DNA preparation is 
of a high quality and purity, and this was a major aim of the initial experiments in this project 
(Chapter 2). These experiments aimed to confirm a high quality of each plasmid as well as 
prepare a large quantity of DNA to avoid any variations caused by different batch preparations. 
Here, I have used the GenCatchTM Plasmid DNA Maxi Prep Kit (Epoch Life Science) for 
plasmid DNA extraction. This kit has been optimised prior to the commencement of my 
project. While the quality of the DNA itself can be a major contributor to cell death during the 
transfection process, this was rigorously rechecked before each transfection experiment and is 
unlikely to have been a reason for the low number of triple-transfected cells.  
 
5.1.1.3 Limitations of Lipofectamine Transient Transfections 
The rationale behind choosing Lipofectamine as the method of transfection in this project was 
based on previous optimisation experiments. In addition to Lipofectamine, mild heat-shock 
and electroporation were previously tested. In the context of those experiments, Lipofectamine 
was found to be the most efficient method. There are other methods of transient transfection, 
such as calcium phosphate. This method has not been previously trialled in the context of our 
methylation-editing experiments in melanoma cell lines. While it is not certain that this will 
improve the transfection efficiency, it is a potential method worth exploration in the future. 
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5.1.1.4 Cell Exposure to Transfection Reagent 
In the transfection experiments of this project, cells of both cell lines were exposed to the 
transfection reagents and DNA complexes for six hours (refer to Chapter 3), after which the 
media was replaced with a fresh aliquot of media and cells were incubated for a total of 72 
hours before FACS preparation. This six-hour exposure time was selected based on previous 
optimisation experiments prior to the commencement of this project. Six hours was found to 
be the optimal exposure time for the cell line WM115 and was applied to this project 
accordingly. The previous optimisation experiments found other melanoma cell lines, for 
example NZM40, to have an optimal exposure time of 12 hours. The second cell line used in 
this project, JL-PRE, had not previously been used for transfection experiments prior to this 
project. Due to the time constraints of this project, optimisation experiments for the exposure 
of transfection reagents unfortunately could not be performed.  
 
Optimal transfection rates can vary between cell lines, and while it is unlikely that this would 
have made a profound impact on the low number of triple-transfected cells observed with this 
cell line, experiments could be performed to optimise reagent exposure time in the context of 
these transfection experiments. 
 
5.1.2 Future Directions 
5.1.2.1 Stable Transfections and Generating Stable Cell Lines 
In the wider context of transfection experiments however, other methods such as lentivirus are 
the ideal choice going forward. While the lentivirus method of transduction was outside the 
scope of this project, it is proven to be a highly efficient method for delivering plasmids into 
mammalian cells. Furthermore, it also has the added advantage of producing stable cell lines. 
The Lipofectamine transfection method is limited in that it does not easily produce stable cell 
lines. Introduction of the lentivirus transduction method to our methylation-editing system will 
be invaluable to future experiments. Not only will it achieve a larger number of transfected 
cells, but stable cell lines are essential for further extensive analyses, such as chromatin 
analysis, that are necessary to investigate the larger context of these experiments in 
investigating the paradoxical relationship between DNA methylation and gene expression.  
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5.1.2.2 Decreasing the Number of Plasmids  
Through the results observed in this project and previous projects, it has become evident that 
the simultaneous transient transfection of three large plasmids is difficult to perform and 
inefficient. Ultimately, the goal of these transfection experiments is to generate enough cells 
for gene expression studies and further chromatin analysis experiments. Therefore, a new 
approach can be proposed whereby the current triple transfection system is replaced with an 
‘all-in-one’ plasmid that expresses all three required components of the dCas9-SunTag system. 
Recently, an all-in-one plasmid that was described by Morita et al. (2016) has become available 
through Addgene.org (Addgene plasmid #82559) (70). This plasmid includes the dCas9-
SunTag, the TET1CD-scFv effector protein, a GFP tag and a cloning site for gRNAs. As a 
future direction, a cloning strategy can be employed to replace the TET1CD-scFv with 
DNMT3A-scFv, in order to obtain both methylation and demethylation systems. Appropriate 
gRNAs can also be cloned in. It is likely that we can expect to observe a much higher 
transfection efficiency with a single plasmid. Further, this system can be used with lentivirus 
transduction as well, so as to have the added advantage of producing stable cell lines. Even 
with transient transfection methods, an all-one-plasmid is relatively simpler to genetically 
manipulate compared to lentivirus particles and can therefore continue to be utilised to trial 
potential gRNAs for effective targeting across numerous genes and within multiple contexts. 
 
5.1.3 FACS and Analysis 
The data acquired from FACS throughout this project is critical to understanding the limitations 
of our method of transfection, and importantly, for planning experiments going forward 
(Chapter 3). Important considerations in the FACS procedure and features which can be 
improved are discussed in this section. 
  
5.1.3.1 Gating for Accurate Identification of Transfected Cells 
Accurate FACS data analysis is built upon the principle of gating. In these experiments, I used 
a negative control sample and a positive control sample to establish accurate gating (described 
in Chapter 3, Section 3.2.2.4). The negative control sample, cells treated with transfection 
reagent but no DNA, was an important control for a number of reasons. Firstly, using a negative 
control for each respective cell line and each individual transfection experiment was essential 
as cells from the same cell line and growing culture tend to exhibit similar behaviour. This 
therefore enabled accurate gating of the true live population of cells. Additionally, since these 
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cells were not transfected with any DNA and therefore would not be positive for any of the 
fluorophores used, they enabled a threshold fluorescence to be established for each respective 
fluorophore. 
 
In addition to a negative control, a positive GFP-expressing control was also used. This 
provides a measure of transfection efficiency, and also compensates for spectral overlap 
between the BFP and GFP channels. This allows the BFP gate to be more accurately set to 
exclude any false-positive cells. This is explained further in the next section. 
 
5.1.3.1.1 mTagBFP for dCas9-SunTag Plasmid and Future Direction 
The BD FACS Aria Fusion (Department of Microbiology and Immunology), is currently not 
equipped with a UV laser. The BFP fluorophore for mTagBFP has an excitation wavelength 
of 383 nm and an emission wavelength of 445 nm. The optimal excitation laser is therefore a 
UV laser which is typically at 355 nm. It is possible to excite BFP with a violet laser (405 nm) 
and detect it in the DAPI channel, which was performed in this project (refer to Chapter 3). 
However, using this excitation laser is not optimal, and is perhaps a reason for the dim signal 
and low number of BFP expressing cells.   
 
Another issue is that there is spectral overlap between BFP and GFP. This can be overcome 
with compensation, which was performed in this project by including a positive control for 
GFP. By using a positive control, and setting gates accordingly, we can remain confident that 
the collected cells were true BFP positive cells. Nevertheless, having no spectral overlap 
between the fluorophores is the most ideal scenario. Therefore, the next steps going forward 
within the context of a three-plasmid transfection experiment, is to change the BFP tag. The 
new tag should not result in any spectral overlap between the other fluorescent signals (GFP 
and RFP), and should be excitable in accordance with the currently equipped lasers on the BD 




5.1.4 Methylation-Specific Illumina Sequencing of EBF3 
Bisulfite-specific Illumina iSeq sequencing was used to investigate a 285 bp region within the 
EBF3 gene promoter region (Chapter 4). This in-depth sequencing was performed to examine 
the methylation status of baseline unedited samples, inactive control samples and samples 
edited with our targeted CRISPR methylation system. 
 
5.1.4.1 Reproducibility of the Illumina Sequencing Assays 
Two independent sequencing runs performed in 2017 and within this project for the entire 
amplicon (285 bp, 34 CpG sites) of WM115 were shown in Chapter 4. Section 4.3.2.3. The 
results were remarkably comparable, showing a very high level of reproducibility between two 
independent replicates that were approximately three years apart. Although only two 
independent replicates were compared, these results are also consistent with the reporting of 
reproducibility throughout the literature (90-93). Therefore, this gives us confidence in the 
accuracy of the Illumina sequencing assay for these experiments. 
 
5.1.4.2 Characteristics of DNA Methylation Changes within the EBF3 Promoter 
The level of average DNA methylation was analysed across the entire 285 bp amplicon (34 
CpG sites) as well as the 58 bp target region (9 CpG sites) for two cell lines. The methylation 
change was compared between unedited and methylation-edited samples as well as the inactive 
control. All changes in the average DNA methylation level were reported as a value of absolute 
difference rather than a relative change. Only one replicate was available for each respective 
sample within each cell line, and as such no statistical analysis could be performed. The 
immediate future direction for all samples will be to perform further independent replicates to 
demonstrate whether the trends observed in this project are both accurate and reproducible.  
 
5.1.4.2.1 Methylation Changes in WM115 
For the WM115 cell line, both the edited and inactive control samples displayed a difference 
compared to the unedited sample, both within the 285 bp amplicon and the 58 bp target region. 
The samples of cells that were combined for sequencing included cells which were transfected 
with two gRNAs (gRNA_474+ and 472-).  
 
Previous work with our demethylation system involved the design of six gRNAs, and different 
levels of demethylation were observed for the different gRNA molecules across different cell 
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lines (72). The six gRNAs were initially designed to target different sites within the EBF3 
promoter region. However, as the samples were mixed, no determination can be made about 
the targeting ability of the independent gRNAs or the effect of sequencing results on combining 
two gRNA molecules. Upon improving the transfection efficiency of this methylation system, 
comparing the function of different gRNA molecules on different cell lines is a direction worth 
exploring.  
 
An increase in average methylation was observed for the edited samples across both the target 
region and the entire amplicon. Interestingly, a greater increase was observed across the entire 
amplicon (14.8%) compared to the target region (8.2%). This might be due to  the presence of 
cells edited with different gRNA molecules, as it is likely that different gRNAs will be more 
or less efficient at targeting the 58 bp region. A possible explanation for this is that the dCas9 
protein footprint may be obscuring methylation changes at the target region (58). However, 
without independent replicates, it is difficult to confirm this observation.  
 
Interestingly, the inactive control sample for this cell line displayed a 33.2% average 
methylation level across the target region, which is substantially lower than that of the unedited 
sample (58.0%). It is possible that this is a result of amplification from cells that are non-
representative of the entire population, i.e. sampling error. This is an especially relevant 
consideration due to the nature of methylation within the target region of this particular cell 
line. WM115 displays a baseline average methylation level of 58% within the EBF3 target 
region, which is a value representing a rather heterogenous cell population (i.e. for example, 
some cells within the population display ~30% methylation and some could ~80%, leading to 
an average of about ~60%.).  
 
It is also possible however, that the inactive control is causing methylation changes within the 
cell. To propose this as a consideration, it is important to discuss the nature of the inactive 
control sample. These cells were transfected with a functional dCas9-SunTag plasmid, a 
functional gRNA plasmid and an inactivated DNMT3A plasmid. We would expect the 
CRISPR-dCas9 machinery and gRNA to be expressed in the cell and function normally, 
meaning they would bind to the DNA. The binding of the CRISPR machinery itself to the DNA 
strand may be recruiting TET enzymes to the site and causing demethylation at particular CpG 
sites. The more likely possibility is that the inactivated DNMT3A protein, although lacking its 
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catalytic domain, may be interfering with the function of the endogenous DNMT3A enzymes 
to methylate at particular CpG sites. 
 
It is important to note that recent literature that have used the dCas9-SunTag-DNMT3A system 
for targeted methylation editing did not use the inactive DNMT3A control for comparison and 
edited cells were instead only compared to unedited baseline cells (56-64). Therefore, at this 
stage, it is not possible to infer with reference to previous published work the mechanisms that 
could be occurring with the inactive control sample.  
 
To overcome the possible PCR amplification bias as a possible explanation for this result, this 
experiment will need to be repeated with a greater number of triple-transfected cells. This will 
subsequently increase confidence that the transfected cells are indeed representative of the 
entire population of cells. Repetition of these experiments will then be able to shed insight into 
whether this is a true reflection of the inactive control sample.  
 
5.1.4.2.2 Methylation Changes in JL-PRE 
For the JL-PRE cell line, data was available for the edited, inactive control and unedited 
samples. Both edited and inactive control samples were targeted with a single gRNA molecule 
(gRNA_472).  
 
A greater increase in methylation was observed in the edited samples for this cell line across 
both the entire amplicon and the target region. An average methylation change of 38.0% 
occurred in the target region, and a 17.4% change across the entire amplicon. Upon comparison 
to the WM115 cell line, this appears to be a much greater change in average methylation. While 
it is possible that our methylation system was more effective in this cell line, this result is likely 
due to the baseline average methylation of this cell line being much lower across both the target 
region (7.4%) and the entire amplicon (10.9%). This is an unsurprisingly result, as targeted 
methylation-editing may merely be more effective in regions already low in methylation. 
 
With regard to the inactive control sample for this cell line, there was an increase in methylation 
observed compared to the unedited cells. In the target region, the inactive control increased to 
37.7%. This is still less than the edited sample, however it is substantially more than the 
unedited cells. Compared to the previous demethylation experiments performed in our 
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laboratory, this result appears to be a much greater difference observed between inactive 
control and unedited samples (72). As discussed previously, one possibility is the interaction 
of the inactive control system with endogenous DNMT3A enzymes. However once again, these 
experiments will need to be repeated before any genuine observations can be made.  
 
5.1.4.3 Effect of Low Cell Input on iSeq Sequencing  
The results described in Chapter 4, Section 4.3.2.7 show the effect of having a very low number 
of FACS collected cells on the sequencing results obtained in this project. For the unedited 
control samples in both WM115 and JL-PRE cell lines, a clear and variable methylation pattern 
across the entire amplicon is observed. This is reflective of the large and heterogeneous cell 
population of which DNA was extracted from for sequencing.  
 
In contrast, as we observe results from samples which contained DNA from a very low number 
of cells, the patterns of DNA methylation appear very similar and cluster into distinct groups. 
This suggests that the sequencing performed may have only assessed the methylation pattern 
of a small number of distinct cells. These results are likely due to PCR amplification bias and 
losses during the iSeq library preparation. Of particular importance is the potential damage to 
the DNA that occurs during the bisulfite conversion process. Bisulfite conversion fragments 
the DNA, and a proportion of that DNA is certainly damaged and lost during this process. 
Therefore, it is not possible that all cells were represented in the sequencing results. This 
particularly becomes a problem when there is a low number of cells of which DNA is available 
for, as the sequencing is dependent on PCR amplification.  
 
With such a low number of cells, it is likely that the same DNA from the same few cells is 
being amplified during PCR, and hence resulting in the same pattern of DNA methylation 
observed across the reads. This scenario was particularly likely when visualising heatmaps for 
the WM115 edited and inactive control samples (Figure 4.13), however this cannot be 
definitely concluded without creating additional biases. The identical patterns of methylation 
appear to be present more in the WM115 unedited and inactive control samples (Figure 4.13) 
than JL-PRE respective samples (Figure 4.14), despite there being more cells for the WM115 
samples. This is likely due to chance, and the respective cell numbers are still very low for both 
cell lines, therefore no definitive assumptions can be made about the differences observed here. 
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Furthermore, without reproducing these results with a greater number of cells, it is difficult to 
form accurate conclusions about the methylation changes observed in these samples. 
 
5.2 Promoter Methylation and Corresponding Expression in 
EBF3 
This work represents the first experiments with the DNMT3A system for targeted methylation 
of EBF3 in melanoma cell lines. While I was able to observe targeted methylation editing, 
albeit with only single replicates, this does not provide any insight into the original overarching 
hypothesis to investigate the relationship between DNA methylation and corresponding 
expression levels of EBF3. Extracting RNA and performing gene expression studies was not 
possible on the limited number of triple-transfected cells, and this was unfortunately unable to 
be repeated within the time constraints of this project. However, this work lays an important 
platform for investigating this relationship in the near future. I am therefore confident, that 
upon improving transfection efficiency, whether through lentivirus transduction or through 
reducing the number of plasmids, performing gene expression studies will not be limited for 
much longer. 
 
Although this project has not provided data on corresponding EBF3 expression changes, the 
hypothesis still remains. From the currently available data on the UCSC Genome Browser 
information sets, there appears to be no evidence to suggest that EBF3 has an alternative 
transcript generated from another TSS. Additionally, other databases such as GeneHancer only 
contain one identifiable TSS and promoter region (94). Based on publicly available data, an 
alternative promoter region for EBF3 does not appear to exist. Therefore, there is currently no 
evidence to suggest that an alternative promoter region is responsible for the changes in EBF3 
transcription observed in melanoma (27). On the contrary, according to the UCSC Genome 
Browser, the 58 bp region of EBF3 targeted in this project is known for interaction with 
multiple transcription factors and enhancer elements. Therefore, the hypothesis that an increase 
in promoter methylation in the EBF3 target region will cause an increase in expression still 
remains, and it most likely occurs via the prevention of transcription factors from binding or 






Overall, I have been able to successfully transfect two melanoma cell lines with a CRISPR-
dCas9-SunTag system for targeted methylation and observe a potential site-specific gain of 
methylation at the target EBF3 region, achieving up to 38.0% increase in methylation. 
Furthermore, I have been able to compare and confirm the EBF3 promoter methylation status 
in two human melanoma cell lines to previous data, as well as purify and confirm two 
constructs for the DNMT3A system. 
 
This work has provided important groundwork for future gene expression studies to investigate 
the paradoxical relationship between DNA methylation and transcriptional activation. 
Investigations which will be possible in the near future include increased transfection 
efficiencies through the application of lentivirus transduction and decreasing the number of 
plasmids required for transient transfection. Following this, gene expression studies and other 
investigations such as chromatin analysis will be possible to further understand the role of 
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Appendix A: Primers for Target-Insert Sanger Sequencing 
Shown are the 18 primer sequences designed to sequence across the DNMT3A and 
DNMT3A_IM coding sequences. Primers are named based on whether they are in the forward 
(for) or reverse (rev) direction, and in accordance with their base position within the coding 
sequence. (For example, Dnmt3a_for_205 is a forward primer with respect to base position 
205 within the DNMT3A coding sequence). All 18 primers sequence across DNMT3A, while 
only a few primers sequence across DNMT3A_IM, as the DNMT3A_IM insert is a truncated 
variant of DNMT3A. 
 






















Appendix B: Shell Script for Illumina iSeq Data Processing 
Shown below is the shell script used for the iSeq sequencing data processing (Chapter 4). This 
was a template provided by Rob Weeks (Department of Pathology, University of Otago) and 
modified by Jim Smith (Alumni, Chatterjee Lab Group, University of Otago). Annotations are 
included on lines beginning with #. 
 
